var title_f0_62_1000="Isotretinoin: Drug information";
var content_f0_62_1000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isotretinoin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33318?source=see_link\">",
"    see \"Isotretinoin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/33/19991?source=see_link\">",
"    see \"Isotretinoin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Absorica&trade;;",
"     </li>",
"     <li>",
"      Amnesteem&reg;;",
"     </li>",
"     <li>",
"      Claravis&trade;;",
"     </li>",
"     <li>",
"      Myorisan&trade;;",
"     </li>",
"     <li>",
"      Sotret&reg;;",
"     </li>",
"     <li>",
"      Zenatane&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accutane&reg;;",
"     </li>",
"     <li>",
"      Clarus&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F185219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Retinoic Acid Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F185182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne, severe recalcitrant nodular:",
"     </b>",
"     Oral: 0.5-1 mg/kg/day in 2 divided doses for 15-20 weeks; may discontinue earlier if the total cyst count decreases by 70%. Adults with very severe disease/scarring or primarily involves the trunk may require dosage adjustment up to 2 mg/kg/day. A second course of therapy may be initiated after a period of &ge;2 months off therapy. A dose of &le;0.5 mg/kg/day may be used to minimize initial flaring (Strauss, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne, moderate (unlabeled use):",
"     </b>",
"     Oral: 20 mg/day (~0.3-0.4 mg/kg/day) for 6 months (Amichai, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F185200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/33/19991?source=see_link\">",
"      see \"Isotretinoin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne, severe recalcitrant nodular:",
"     </b>",
"     Children 12-17 years: Oral: 0.5-1 mg/kg/day in 2 divided doses for 15-20 weeks; may discontinue earlier if the total cyst count decreases by 70%. A second course of therapy may be initiated after a period of &ge;2 months off therapy. A dose of &le;0.5 mg/kg/day may be used to minimize initial flaring (Strauss, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne, moderate (unlabeled use):",
"     </b>",
"     Children 12-17 years: Oral: 20 mg/day (~0.3-0.4 mg/kg/day) for 6 months (Amichai, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuroblastoma, high-risk (unlabeled use):",
"     </b>",
"     Children 1-17 years: Oral: 160 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (in 2 divided doses) days 1 through 14 every 28 days for 6 cycles, beginning after continuation chemotherapy or transplantation (Matthay, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F185183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13829623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F185184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hepatic impairment prior to treatment:",
"     </i>",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hepatotoxicity during treatment:",
"     </i>",
"     Liver enzymes may normalize with dosage reduction or with continued treatment; discontinue if normalization does not readily occur or if hepatitis is suspected.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorica&trade;: 10 mg, 20 mg, 30 mg, 40 mg [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claravis&trade;: 10 mg, 20 mg, 30 mg, 40 mg [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myorisan&trade;: 10 mg, 20 mg, 40 mg [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amnesteem&reg;: 10 mg, 20 mg, 40 mg [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sotret&reg;: 10 mg, 20 mg, 30 mg, 40 mg [contains parabens, soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zenatane&trade;: 10 mg, 20 mg, 40 mg [contains soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. All patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE&trade; risk management program, designed to eliminate fetal exposures to isotretinoin. This program covers all isotretinoin products (brand and generic). The iPLEDGE&trade; program requires that all patients meet qualification criteria and monthly program requirements (eg, pregnancy testing). Healthcare providers can only prescribe a maximum 30-day supply at each monthly visit and must counsel patients on the iPLEDGE&trade; program requirements and confirm counseling via the iPLEDGE&trade; automated system. Registration, activation, and additional information are provided at www.ipledgeprogram.com or by calling 866-495-0654.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Absorica&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM306859.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM306859.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Accutane&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085812.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085812.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Sotret&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089135.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089135.pdf`",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F185157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally with a meal (except Absorica&trade; which may be taken without regard to meals). According to the manufacturers&rsquo; labeling, capsules should be swallowed whole with a full glass of liquid. For patients unable to swallow capsule whole, an oral liquid may be prepared; may irritate esophagus if contents are removed from the capsule.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F185156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of severe recalcitrant nodular acne unresponsive to conventional therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F185216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate degrees of treatment-resistant acne, management of acne that produces physical or psychological scarring; treatment of cutaneous T-cell lymphomas (mycosis fungoides and S&eacute;zary syndrome); prevention of squamous cell skin cancers (in high-risk patients); treatment of high-risk neuroblastoma in children",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Accutane&reg; may be confused with Accolate&reg;, Accupril&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Claravis&trade; may be confused with Cleviprex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ISOtretinoin may be confused with tretinoin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;\">",
"       Isotretinoin may be confused with tretinoin (which is also called all-",
"       <i>",
"        trans",
"       </i>",
"       retinoic acid, or ATRA ); while both products may have uses in cancer treatment, they are",
"       <b>",
"        not",
"       </b>",
"       interchangeable.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F185217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, flushing, palpitation, stroke, syncope, tachycardia, vascular thrombotic disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggressive behavior, depression, dizziness, drowsiness, emotional instability, fatigue, headache, insomnia, lethargy, malaise, nervousness, paresthesia, pseudotumor cerebri, psychosis, seizure, stroke, suicidal ideation, suicide attempts, suicide, violent behavior",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Abnormal wound healing acne fulminans, alopecia, bruising, cheilitis, cutaneous allergic reactions, dry nose, dry skin, eczema, eruptive xanthomas, facial erythema, fragility of skin, hair abnormalities, hirsutism, hyperpigmentation, hypopigmentation, increased sunburn susceptibility, nail dystrophy, paronychia, peeling of palms, peeling of soles, photoallergic reactions, photosensitizing reactions, pruritus, purpura, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (25%), abnormal menses, blood glucose increased, cholesterol increased, HDL decreased, hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bleeding and inflammation of the gums, colitis, esophagitis, esophageal ulceration, inflammatory bowel disease, nausea, nonspecific gastrointestinal symptoms, pancreatitis, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Nonspecific urogenital findings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), anemia, neutropenia, pyogenic granuloma, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, GGTP increased, hepatitis, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (29% in pediatric patients), arthralgia, arthritis, bone abnormalities, bone mineral density decreased, calcification of tendons and ligaments, CPK increased, myalgia, premature epiphyseal closure, skeletal hyperostosis, tendonitis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis (4%), blepharitis (1%), chalazion (1%), hordeolum (1%), cataracts, color vision disorder, corneal opacities, eyelid inflammation, keratitis, night vision decreased, optic neuritis, photophobia, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing impairment, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glomerulonephritis, hematuria, proteinuria, pyuria, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasms, epistaxis, respiratory infection, voice alteration, Wegener's granulomatosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactic reactions, disseminated herpes simplex, diaphoresis, infection, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal meibomian gland secretion, erythema multiforme, meibomian gland atrophy, myopia, pseudotumor cerebri, Stevens-Johnson syndrome, toxic epidermal necrolysis, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F185160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isotretinoin or any component of the formulation; sensitivity to parabens, vitamin A, or other retinoids; pregnant women or those who may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F185143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Auditory impairment: Hearing impairment, which can continue after therapy is discontinued, may occur. Discontinue therapy if hearing impairment or tinnitus develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone mineral density loss: May decrease bone mineral density; osteoporosis, osteopenia, and bone fractures have been reported with use. Use caution in patients with a genetic predisposition to bone disorders (eg, osteoporosis, osteomalacia) and with disease states or concomitant medications that can induce bone disorders. Patients may be at risk when participating in activities with repetitive impact (such as sports).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic effects: Rare postmarketing cases of severe skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), including fatalities, have been reported; monitor for severe skin reactions; discontinue use if severe skin reaction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Growth effects: Skeletal hyperostosis and premature epiphyseal closure have also been reported with the use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Clinical hepatitis and elevated liver enzymes have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylaxis and other types of allergic reactions, including cutaneous reactions and allergic vasculitis, have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inflammatory bowel disease: Has been reported with use; discontinue treatment if abdominal pain, rectal bleeding, or severe diarrhea occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Vision impairment, corneal opacities, decreased tolerance to contact lenses (due to dry eyes), and decreased night vision have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudotumor cerebri: Retinoids have been associated with pseudotumor cerebri (benign intracranial hypertension), especially in children. Concurrent use of other drugs associated with this effect (eg, tetracyclines) may increase risk. Early signs and symptoms include papilledema, headache, nausea, vomiting and visual disturbances; discontinue if papilledema occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric effects: May cause depression, psychosis, aggressive or violent behavior, and changes in mood. Rarely, suicidal thoughts and actions have been reported during isotretinoin usage. All patients should be observed closely for symptoms of depression or suicidal thoughts. Discontinuation of treatment alone may not be sufficient, further evaluation may be necessary. Use with extreme caution in patients with a history of psychiatric disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; impaired glucose control has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertriglyceridemia: Use with caution in patients with hypertriglyceridemia; acute pancreatitis and fatal hemorrhagic pancreatitis (rare) have been reported; discontinue therapy if severe hypertriglyceridemia or symptoms of pancreatitis occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tetracyclines: Pseudotumor cerebri (benign intracranial hypertension) has been reported with use of isotretinoin in combination with tetracyclines; concomitant use should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warnings]: Birth defects (facial, eye, ear, skull, central nervous system, cardiovascular, thymus and parathyroid gland abnormalities) have been noted following isotretinoin exposure during pregnancy and the risk for severe birth defects is high, with any dose or even with short treatment duration. Low IQ scores have also been reported. The risk for spontaneous abortion and premature births is increased. Because of the high likelihood of teratogenic effects, all patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE&trade; risk evaluation and mitigation strategy (REMS) program; do not prescribe isotretinoin for women who are or who are likely to become pregnant while using the drug. If pregnancy occurs during therapy, isotretinoin should be discontinued immediately and the patient referred to an obstetrician-gynecologist specializing in reproductive toxicity.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorica&trade;: Absorption is ~83% greater than Accutane&reg; when administered under fasting conditions; they are bioequivalent when taken with a high-fat meal. Absorica&trade; is",
"     <b>",
"      not",
"     </b>",
"     interchangeable with other generic isotretinoin products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchange: Isotretinoin and tretinoin (which is also known as all-",
"     <i>",
"      trans",
"     </i>",
"     retinoic acid, or ATRA) may be confused, while both products may be used in cancer treatment, they are",
"     <b>",
"      not",
"     </b>",
"     interchangeable; verify product prior to dispensing and administration to prevent medication errors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood donation: Patients should be instructed not to donate blood during therapy and for 1 month following discontinuation of therapy due to risk of donated blood being given to a pregnant female.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: This medication should only be prescribed by prescribers competent in treating severe recalcitrant nodular acne and experienced with the use of systemic retinoids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Safety of long-term use is not established and is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Because of the high likelihood of teratogenic effects, all patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE&trade; risk evaluation and mitigation strategy (REMS) management program; do not prescribe isotretinoin for women who are or who are likely to become pregnant while using the drug (see Additional Information or Pharmacotherapy Pearls for details).",
"     </b>",
"     Women of childbearing potential must be capable of complying with effective contraceptive measures. Patients must select and commit to two forms of contraception. Therapy is begun after two negative pregnancy tests; effective contraception must be used for at least 1 month before beginning therapy, during therapy, and for 1 month after discontinuation of therapy. Prescriptions should be written for no more than a 30-day supply, and pregnancy testing and counseling should be repeated monthly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of ISOtretinoin. Specifically, the risk for elevated triglyceride concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: ISOtretinoin may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: Retinoic Acid Derivatives may enhance the adverse/toxic effect of Vitamin A.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F185173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid or limit ethanol (may increase triglyceride levels if taken in excess).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Isotretinoin bioavailability increased if taken with food or milk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization and may decrease the effectiveness of oral contraceptives). Additional vitamin A supplements may lead to vitamin A toxicity (dry skin, irritation, arthralgias, myalgias, abdominal pain, hepatic changes); avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F185163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Major fetal abnormalities (both internal and external), spontaneous abortion and premature births  have been reported.",
"     <b>",
"      [U.S. Boxed Warnings]: Birth defects (facial, eye, ear, skull, central nervous system, cardiovascular, thymus and parathyroid gland abnormalities) have been noted following isotretinoin exposure during pregnancy and the risk for severe birth defects is high, with any dose or even with short treatment duration. Low IQ scores have also been reported. The risk for spontaneous abortion and premature births is increased. Because of the high likelihood of teratogenic effects, all patients (male and female), prescribers, wholesalers, and dispensing pharmacists must register and be active in the iPLEDGE&trade; risk evaluation and mitigation strategy (REMS) program; do not prescribe isotretinoin for women who are or who are likely to become pregnant while using the drug. If pregnancy occurs during therapy, isotretinoin should be discontinued immediately and the patient referred to an obstetrician-gynecologist specializing in reproductive toxicity.",
"     </b>",
"     This medication is contraindicated in females of childbearing potential unless they are able to comply with the guidelines of the iPLEDGE&trade; pregnancy prevention program. Females of childbearing potential should not become pregnant during therapy or for 1 month following discontinuation of isotretinoin. Upon discontinuation of treatment, females of childbearing potential should have a pregnancy test after their last dose and again one month after their last dose. Two forms of contraception should be continued during this time. Any pregnancies should be reported to the iPLEDGE&trade; program (www.ipledgeprogram.com or 866-495-0654).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F185188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13829619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if isotretinoin is excreted in breast milk. Due to the potential for adverse reactions, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F185164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food, except Absorbica&trade; which may be taken without regard to meals. Limit intake of vitamin A; avoid use of other vitamin A products. Some formulations may contain soybean oil.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Absorica Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $790.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $790.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $850.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $850.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Amnesteem Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $540.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $641.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $744.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Claravis Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $492.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $583.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $493.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $677.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Myorisan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $540.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $641.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $744.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F185152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, baseline sedimentation rate, glucose, CPK; signs of depression, mood alteration, psychosis, aggression, severe skin reactions",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Pregnancy test (for all female patients of childbearing potential): Two negative tests with a sensitivity of at least 25 mIU/mL prior to beginning therapy (the second performed at least 19 days after the first test and performed during the first 5 days of the menstrual period immediately preceding the start of therapy); monthly tests to rule out pregnancy prior to refilling prescription.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Lipids: Prior to treatment and at weekly or biweekly intervals until response to treatment is established. Test should not be performed &lt;36 hours after consumption of ethanol.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Liver function tests: Prior to treatment and at weekly or biweekly intervals until response to treatment is established.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F185165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Accunetan (KP);",
"     </li>",
"     <li>",
"      Acnal SC (KP);",
"     </li>",
"     <li>",
"      Acnetrex (PH);",
"     </li>",
"     <li>",
"      Acnotin (HK, SG, TH);",
"     </li>",
"     <li>",
"      Acugen (PH);",
"     </li>",
"     <li>",
"      Akinol (KP);",
"     </li>",
"     <li>",
"      Aknenormin (DE);",
"     </li>",
"     <li>",
"      Contracne (FR);",
"     </li>",
"     <li>",
"      Curacne Ge (FR);",
"     </li>",
"     <li>",
"      Curatane (IL);",
"     </li>",
"     <li>",
"      Isoface (DO, EC, GT, MX, PA, PE, SV);",
"     </li>",
"     <li>",
"      Isotane (TH);",
"     </li>",
"     <li>",
"      Isotina (KP);",
"     </li>",
"     <li>",
"      Isotinon (KP);",
"     </li>",
"     <li>",
"      Isotren (KP);",
"     </li>",
"     <li>",
"      Isotret-Hexal (DE);",
"     </li>",
"     <li>",
"      Isotrex (AR, AU, BR, CL, CR, DK, GB, ID, IE, LU, MX, NI, PK, SG, TW);",
"     </li>",
"     <li>",
"      Isotrex Gel (AT, CO, DE, FR, HK, IL, IT, MY, NZ, PH, PL, TH);",
"     </li>",
"     <li>",
"      Isotroin (IN);",
"     </li>",
"     <li>",
"      Neotrex (MX);",
"     </li>",
"     <li>",
"      Nimegen (MY, SG);",
"     </li>",
"     <li>",
"      Oratane (AU, MY, NZ, SG);",
"     </li>",
"     <li>",
"      Procuta Ge (FR);",
"     </li>",
"     <li>",
"      Reducar (HK);",
"     </li>",
"     <li>",
"      Roaccutan (AR, AT, CO, DK, EC, FI, HU, IT, MX, NO, PE, PT, PY, UY, VE);",
"     </li>",
"     <li>",
"      Roaccutane (AE, AU, BB, BE, BG, BH, BM, BS, BZ, CH, CY, CZ, EE, EG, FR, GB, GH, GR, GY, HK, HR, IE, IL, IQ, IR, JM, JO, KE, KP, KW, LB, LU, LY, NL, OM, PH, PL, PR, QA, SA, SR, SY, TH, TR, TT, TW, TZ, UG, YE, ZM);",
"     </li>",
"     <li>",
"      Roaccuttan (CO);",
"     </li>",
"     <li>",
"      Roacnetan (CN);",
"     </li>",
"     <li>",
"      Roacutan (BR, ES);",
"     </li>",
"     <li>",
"      Roacuttan (HN);",
"     </li>",
"     <li>",
"      Sotret (TH);",
"     </li>",
"     <li>",
"      Sotrexe (MX);",
"     </li>",
"     <li>",
"      Tretin (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F185142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces sebaceous gland size and reduces sebum production in acne treatment; in neuroblastoma, decreases cell proliferation and induces differentiation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F185159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Enhanced with a high-fat meal; Absorica&trade; absorption is ~83% greater than Accutane&reg; when administered under fasting conditions; they are bioequivalent when taken with a high-fat meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99% to 100%; primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2B6, 2C8, 2C9, 2D6, 3A4; forms metabolites; major metabolite: 4-oxo-isotretinoin (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Parent drug: 21 hours; Metabolite: 21-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (equal amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Retinoid Therapy for Severe Dermatological Disorders,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 90(1 Pt 1):119-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/1535432/pubmed\" id=\"1535432\" target=\"_blank\">",
"        1535432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amichai B, Shemer A, and Grunwald MH, &ldquo;Low-Dose Isotretinoin in the Treatment of Acne Vulgaris,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2006, 54(4):644-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/16546586/pubmed\" id=\"16546586\" target=\"_blank\">",
"        16546586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castleberry RP, Emanuel PD, Zuckerman KS, et al, &ldquo;A Pilot Study of Isotretinoin in the Treatment of Juvenile Chronic Myelogenous Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(25):1680-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/7605422/pubmed\" id=\"7605422\" target=\"_blank\">",
"        7605422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiGiovanna JJ and Peck GL, &ldquo;Oral Synthetic Retinoid Treatment in Children,&rdquo;",
"      <i>",
"       Pediatr Dermatol",
"      </i>",
"      , 1983, 1(1):77-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/6238291/pubmed\" id=\"6238291\" target=\"_blank\">",
"        6238291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hendrix CW, Jackson KA, Whitmore E, et al, &ldquo;The Effect of Isotretinoin on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Norethindrone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2004, 75(5):464-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/15116059/pubmed\" id=\"15116059\" target=\"_blank\">",
"        15116059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lammer EJ, Chen DT, Hoar RM, et al, &ldquo;Retinoic Acid Embryopathy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1985, 313(14):837-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/3162101/pubmed\" id=\"3162101\" target=\"_blank\">",
"        3162101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee AG, &ldquo;Pseudotumor Cerebri After Treatment With Tetracycline and Isotretinoin for Acne,&rdquo;",
"      <i>",
"       Cutis",
"      </i>",
"      , 1995, 55(3):165-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/7634848/pubmed\" id=\"7634848\" target=\"_blank\">",
"        7634848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lotan R, Xu XC, Lippman SM, et al, &ldquo;Suppression of Retinoic Acid Receptor-Beta in Premalignant Oral Lesions and Its Up-Regulation by Isotretinoin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(21):1405-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/7723796/pubmed\" id=\"7723796\" target=\"_blank\">",
"        7723796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matthay KK, Villablanca JG, Seeger RC, et al, \"Treatment of High-Risk Neuroblastoma With Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-",
"      <i>",
"       cis",
"      </i>",
"      -Retinoic Acid. Children's Cancer Group,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(16):1165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/10519894/pubmed\" id=\"10519894\" target=\"_blank\">",
"        10519894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell AA, Van Bennekom CM, Louik C, et al, &ldquo;A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(2):101-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/7777014/pubmed\" id=\"7777014\" target=\"_blank\">",
"        7777014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al, \"Ocular Adverse Effects of Systemic Treatment With Isotretinoin,\"",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/22508771/pubmed\" id=\"22508771\" target=\"_blank\">",
"        22508771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rappaport EB and Knapp M, &ldquo;Isotretinoin Embryopathy - A Continuing Problem,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1989, 29(5):463-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/2738179/pubmed\" id=\"2738179\" target=\"_blank\">",
"        2738179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strauss JS, Krowchuk DP, Leyden JJ, et al, &ldquo;Guidelines of Care for Acne Vulgaris Management,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2007, 56(4):651-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/17276540/pubmed\" id=\"17276540\" target=\"_blank\">",
"        17276540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yu AL, Gilman AL, Ozkaynak MF, et al, &ldquo;Anti-GD2 Antibody With GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(14):1324-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/20879881/pubmed\" id=\"20879881\" target=\"_blank\">",
"        20879881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang C and Duvic M, &ldquo;Treatment of Cutaneous T-Cell Lymphoma With Retinoids,&rdquo;",
"      <i>",
"       Dermatol Ther",
"      </i>",
"      , 2006, 19(5):264-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/1000/abstract-text/17014481/pubmed\" id=\"17014481\" target=\"_blank\">",
"        17014481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8582 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_1000=[""].join("\n");
var outline_f0_62_1000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708957\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185177\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185178\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185219\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185182\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185200\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185183\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13829623\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185184\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185155\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185139\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234007\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874644\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185157\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185156\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185216\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185227\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185217\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185160\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185143\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299550\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185148\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185173\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185150\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185163\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185188\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13829619\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185164\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323242\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185152\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185165\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185142\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185159\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8582|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33318?source=related_link\">",
"      Isotretinoin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/33/19991?source=related_link\">",
"      Isotretinoin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_62_1001="Herpes simplex virus type 1 encephalitis";
var content_f0_62_1001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Herpes simplex virus type 1 encephalitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/1001/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/1001/contributors\">",
"     Robyn S Klein, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/1001/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/1001/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/1001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/1001/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/62/1001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 1 (HSV-1) encephalitis is the most common cause of sporadic fatal encephalitis worldwide. The clinical syndrome is often characterized by the rapid onset of fever, headache, seizures, focal neurologic signs, and impaired consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/1\">",
"     1",
"    </a>",
"    ]. HSV-1 encephalitis is a devastating disease with significant morbidity and mortality, despite available antiviral therapy.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, diagnosis, and treatment of HSV-1 encephalitis will be reviewed here. Neonatal encephalitis and other manifestations of HSV-1 infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 encephalitis is the most common cause of fatal sporadic encephalitis in the United States, accounting for approximately 10 to 20 percent of the 20,000 annual viral encephalitis cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The infection arises in all age groups, with one-third of all cases occurring in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/4\">",
"     4",
"    </a>",
"    ]. HSV is also the most commonly identified pathogen among hospitalized patients diagnosed with encephalitis in Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/5\">",
"     5",
"    </a>",
"    ]. In a nationwide retrospective study of the incidence of HSV-1 encephalitis in Sweden over a 12-year period (1990 to 2001), the incidence of confirmed cases was 2.2 per million population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nearly all cases of herpes encephalitis beyond the neonatal period, the etiologic agent is herpes simplex virus type 1 (HSV-1). In neonates, herpes encephalitis may be caused by either HSV-1 or HSV-2.",
"   </p>",
"   <p>",
"    HSV-2 produces a more global encephalitis with significant neurologic impairment. In one series of 24 infants with HSV encephalitis and a mean follow-up of 19 months, only 4 of 14 (28 percent) survivors with HSV-2 encephalitis were neurologically normal compared to nine of nine infants with HSV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Routes of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV infection of the central nervous system (CNS) appears to arise via one of three routes, each accounting for approximately one-third of infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate CNS invasion via the trigeminal nerve or olfactory tract following an episode of primary HSV-1 of the oropharynx; most patients with primary infection are younger than 18 years of age",
"     </li>",
"     <li>",
"      CNS invasion after an episode of recurrent HSV-1 infection, which is believed to represent viral reactivation with subsequent spread",
"     </li>",
"     <li>",
"      CNS infection without primary or recurrent HSV-1 infection, which is felt to represent reactivation of latent HSV in situ within the CNS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, necrosis occurs in the temporal lobe with clinical deficits consistent with the areas damaged.",
"   </p>",
"   <p>",
"    Various animal models have been developed that attempt to mimic these possible routes of infection. One murine model demonstrated that installation of HSV-1 into the nares of certain strains of mice produces focal lesions localized to the temporal lobe, similar to those observed in human cases of HSV-1 encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/8\">",
"     8",
"    </a>",
"    ]. Another murine model has shown that inoculation of HSV into the murine tooth pulp leads to an encephalitis primarily affecting the temporal cortex and limbic system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/9\">",
"     9",
"    </a>",
"    ]. This manner of inoculation selectively infects the mandibular division of the trigeminal nerve, which is both the most commonly infected division of the trigeminal nerve and the most common site of viral latency in humans with HSV-1 infections.",
"   </p>",
"   <p>",
"    Another possible mechanism of nervous system invasion is viremia. HSV has been identified by culture in the blood of neonates and immunocompromised patients and, by polymerase chain reaction, in the blood of immunocompetent adults with gingivostomatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Latent infections with neurovirulent strains of HSV-1 can be reactivated in trigeminal ganglia and central nervous system olfactory centers of rabbits by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in another model system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/12\">",
"     12",
"    </a>",
"    ]. Although this model mimics human disease with focal brain necrosis restricted to the temporal lobes, it requires immunosuppressive drugs to initiate infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/12\">",
"     12",
"    </a>",
"    ]. However, in humans HSV-1 encephalitis is not more common in immunosuppressed than immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Host susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toll-like receptors (TLRs) are important in the innate immune response. TLR3 is expressed in the CNS, where it may prevent spread of HSV from the epithelium to the brain via cranial nerves through the generation of interferons. Two specific immunodeficiencies, UNC-93B1 deficiency and mutations in TLR3, can predispose children to HSV encephalitis. UNC-93B is a protein involved in the intracellular trafficking of TLR3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link&amp;anchor=H20#H20\">",
"     \"Toll-like receptors: Roles in disease and therapy\", section on 'Primary immunodeficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link&amp;anchor=H5549596#H5549596\">",
"     \"Toll-like receptors: Roles in disease and therapy\", section on 'UNC93B deficiency and TLR3 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two cases of HSV-1 encephalitis have been reported in patients taking tumor necrosis factor-alpha (TNF-alpha) inhibitors; although the use of TNF-alpha inhibitors has been associated with tuberculosis and other infections, the relationship of HSV-1 infection to these medications is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tissue injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the brain damage from CNS HSV-1 infection may be immune mediated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/8\">",
"     8",
"    </a>",
"    ], which may explain the observation that HSV-1 encephalitis is not more common among the immunosuppressed despite the frequency of mucocutaneous HSV-1 infections in these hosts. Indeed, HSV encephalitis in immunocompromised patients sometimes follows a different clinical course characterized by a slow evolution with only mild histopathologic changes observed on biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the pathogenesis of HSV encephalitis is not fully understood, it is felt that both direct virus-mediated and indirect immune-mediated mechanisms play a role in producing CNS damage [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ]. It is unclear whether the extent of CNS viral load is directly related to the severity of tissue damage. In one study of eight patients with HSV encephalitis, the level of HSV-1 viremia in CSF, as determined by PCR, did not correlate with the severity of clinical signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of lines of evidence support immune-mediated damage in the pathogenesis of HSV-1 encephalitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HSV-1 encephalitis is characterized by focal inflammatory lesions that are thought to result from the expression of a virus-specific T cell response [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/16\">",
"       16",
"      </a>",
"      ]. As an example, cytotoxic T cells that specifically lyse HSV-infected targets in vitro predominate at focal sites of infection in murine models [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other animal models have demonstrated correlation between production of cytokines and nitric oxide and brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of exogenous interleukin- (IL) 4 to mice intranasally infected with HSV-1 increases the severity of subsequent encephalitis through the increased production of IL-4 from local CD4+ T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Correlations have been noted between the infiltration of immune cells into the CNS during herpes virus infection and demyelination in the mouse model [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HSV-1 IgM immune complexes were localized in cerebrovascular walls in the brain of a patient with herpes encephalitis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study, N-methyl-D-aspartate receptor (NMDAR) IgA, IgG, or IgM antibodies were detected in the serum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CSF of 13 of 44 patients (30 percent) with herpes simplex encephalitis, whereas these antibodies were not detected in any patients with enterovirus or varicella-zoster encephalitis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/20\">",
"       20",
"      </a>",
"      ]. NMDAR antibodies are also associated with a distinct clinical syndrome unrelated to HSV encephalitis, anti-NMDAR encephalitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link&amp;anchor=H3370789#H3370789\">",
"       \"Paraneoplastic and autoimmune encephalitis\", section on 'Anti-NMDA receptor encephalitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal neurologic findings are usually acute (&lt;1 week in duration) and include altered mentation and level of consciousness, focal cranial nerve deficits, hemiparesis, dysphasia, aphasia, ataxia, or focal seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. Over 90 percent of patients will have one of the above symptoms plus fever [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ]. Other associated neurologic symptoms include urinary and fecal incontinence, aseptic meningitis, localized dermatomal rashes, and Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/22\">",
"     22",
"    </a>",
"    ]. Later in the clinical course, patients may have diminished comprehension, paraphasic spontaneous speech, impaired memory, and loss of emotional control [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various behavioral syndromes have been reported in association with HSV-1 encephalitis including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypomania",
"     </li>",
"     <li>",
"      Kl&uuml;ver-Bucy syndrome (KBS)",
"     </li>",
"     <li>",
"      Varying states of amnesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypomanic symptoms often occur in patients during the initial phase of HSV-1 encephalitis, presumably from inflammation of the inferomedial temporal lobe or limbic system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/24\">",
"     24",
"    </a>",
"    ]. Behavior alterations may include an elevated mood, excessive animation, decreased need for sleep, inflated self-esteem, and hypersexuality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    KBS is a behavioral syndrome of varying etiologies, originally described in Rhesus macaques after bilateral temporal lobectomy, which includes \"psychic blindness,\" loss of normal anger and fear responses, and increased sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/23\">",
"     23",
"    </a>",
"    ]. KBS and amnesia are thought to occur secondary to HSV's affinity for the temporal lobe and limbic structures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV-1 CNS infection has also been implicated in cases of recurrent brainstem encephalitis. This condition is characterized by upward gaze palsy and facial numbness, as well as signs of involvement of corticospinal, spinothalamic, lemniscal, and brainstem cerebellar pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the CSF typically shows a lymphocytic pleocytosis, increased number of erythrocytes (in 84 percent of patients), and elevated protein [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/25\">",
"     25",
"    </a>",
"    ]. However, a normal cerebrospinal fluid (CSF) profile can occur early in the course of the disease; this observation has been made in immunocompetent hosts and in a small case series of patients taking tumor necrosis factor (TNF-alpha) inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/13,26\">",
"     13,26",
"    </a>",
"    ]. Repeat testing can be helpful when the clinical suspicion is high. Low glucose is uncommon and may suggest an alternative diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients have serologic evidence of prior infection with HSV-1, consistent with reactivation disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal lobe abnormalities on brain imaging are considered strong evidence for herpes simplex encephalitis. Temporal lobe lesions are predominantly unilateral and may have associated mass effect [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ]. However, extra temporal abnormalities were noted as well in 11 of 20 patients in one retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/27\">",
"     27",
"    </a>",
"    ]. In general, focal radiographic findings are found more often in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cranial CT scans of the brain have only 50 percent sensitivity early in the disease, and the presence of abnormalities is generally associated with severe damage and poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ]. By contrast, MRI is the most sensitive and specific imaging method for HSV encephalitis, especially in the early course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]; although normal MRI findings have been also reported in the setting of disease. Several recent studies indicate that MRI with diffusion-weighted imaging (DWI) may be helpful early in the diagnosis of HSV-1 encephalitis; however, DWI is not superior to conventional MRI for follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain perfusion SPECT studies of patients with viral encephalitis and CSF antibodies to HSV have shown increased accumulation of radiotracer in the affected temporal lobe [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/34\">",
"     34",
"    </a>",
"    ]. These changes have a high specificity; of 540 brains analyzed, unilateral hyperperfusion has been noted only in early HSV encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/34\">",
"     34",
"    </a>",
"    ]. The abnormalities gradually convert over 4 to 10 weeks to subnormal accumulation and are felt to indicate neuronal death with subsequent healing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/34\">",
"     34",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71701 \" href=\"UTD.htm?22/63/23545\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electroencephalogram (EEG)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal electroencephalogram (EEG) findings occur in &gt;80 percent of cases, typically showing prominent intermittent high amplitude slow waves (delta and theta slowing), and, occasionally, continuous periodic lateralized epileptiform discharges in the affected region [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Many EEG findings, however, are nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HSV encephalitis should be considered in the febrile encephalopathic patient with focal findings. However, these clinical findings are not pathognomonic because numerous other infections can mimic HSV encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a classic study of 432 patients who underwent brain biopsy for a presumed diagnosis of herpes encephalitis, 45 percent had HSV isolated from brain tissue, 22 percent had other identifiable causes of their symptoms, and 33 percent remained undiagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is extremely important that the diagnosis of HSV encephalitis be entertained early in any patient who presents with suggestive signs, symptoms, laboratory, and imaging studies since it is among the more treatable of the infectious etiologies of encephalitis.",
"   </p>",
"   <p>",
"    The differential diagnosis is extensive and can include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/21,37\">",
"     21,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Encephalitis from other viral etiologies such as togavirus infections (West Nile encephalitis, St. Louis encephalitis, Western equine encephalitis, California encephalitis, Eastern equine encephalitis), other herpesviruses (CMV, EBV, VZV) and other miscellaneous viruses (enteroviruses, influenza A, mumps, adenovirus, lymphocytic choriomeningitis virus, progressive multifocal leukoencephalopathy caused by the JC virus) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brain abscess or subdural empyema caused by a variety of organisms including bacteria, mycobacteria, fungi, rickettsiae, mycoplasma, or protozoa.",
"     </li>",
"     <li>",
"      Post-infectious conditions such Reye syndrome",
"     </li>",
"     <li>",
"      Acute disseminated encephalomyelitis",
"     </li>",
"     <li>",
"      Subacute sclerosing panencephalitis secondary to defective measles virus",
"     </li>",
"     <li>",
"      Neurosyphilis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Primary or secondary brain tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Paraneoplastic and autoimmune encephalitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link\">",
"       \"Paraneoplastic and autoimmune encephalitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other noninfectious causes such as subdural hematoma, systemic lupus erythematosus, adrenal leukodystrophy, vasculitis, neuro-Beh&ccedil;et&rsquo;s and toxic encephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for establishing the diagnosis is the detection of herpes simplex virus DNA in the CSF by polymerase chain reaction (PCR). The test has extremely high sensitivity (98 percent) and specificity (94 to 100 percent) and is positive early in the course of illness. While awaiting results of PCR testing, treatment for HSV encephalitis should be initiated. When present, HSV DNA is detectable via PCR analysis of the CSF for at least two weeks and up to one month after the onset of clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of PCR for the diagnosis of HSV-1 encephalitis has also led to the identification of atypical forms of HSV-1 encephalitis formerly attributed to alternative viruses including brainstem encephalitis, myelitis, or diffuse encephalitis without temporal lobe involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34789?source=see_link\">",
"     \"PCR testing for the diagnosis of herpes simplex virus in patients with encephalitis or meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Brain biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of PCR testing, brain biopsy was considered to be the only way to accurately diagnose herpes encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/1,46\">",
"     1,46",
"    </a>",
"    ]. Brain biopsy still has a role in patients who have clinical deterioration despite antiviral therapy or when alternative diagnoses are being considered [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain specimens are examined for the presence of HSV by culture, HSV antigens by immunohistochemistry, or viral DNA by in situ hybridization [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/47\">",
"     47",
"    </a>",
"    ]. Pathological examination of involved regions may show areas of mononuclear inflammation with perivascular cuffs and focal infiltrates of inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/35\">",
"     35",
"    </a>",
"    ]. Glial nodules, neuronophagia, and intense lymphocytic infiltrates with regions of necrosis and macrophages may also be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the procedure is invasive and can lead to neurologic sequelae such as intracranial hemorrhage and edema at the biopsy site [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     CSF antigen and antibody determinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSF antigen and antibody determinations are not helpful in the early diagnosis of HSV encephalitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of purified HSV glycoprotein B to detect CSF antibodies has a sensitivity of 97 percent and a specificity of 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/48\">",
"       48",
"      </a>",
"      ]. However, viral antibody titers, which rise fourfold over the course of the illness, are first positive after 10 days to 2 weeks of illness and are thus only helpful retrospectively [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HSV antigen can also be detected in CSF, but sensitivity and specificity of this test is lower than PCR assays [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Viral culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral culture of CSF is rarely positive in the early stages of infection and is only positive later in about 4 to 5 percent of patients with brain biopsy-proven HSV encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/25,37\">",
"     25,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV encephalitis is a devastating infection of the central nervous system. Even with early administration of therapy after onset of disease, nearly two-thirds of survivors will have significant neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/4\">",
"     4",
"    </a>",
"    ]. For this reason, empiric therapy with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 hours) should be initiated as soon as the diagnosis is considered. We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend oral antiviral therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ) for the treatment of HSV encephalitis.",
"   </p>",
"   <p>",
"    As of November 2012, there is a shortage of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the United States due to a manufacturing delay [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. IV acyclovir, if available, is the drug of choice for HSV encephalitis; during this shortage, IV acyclovir should be reserved for patients with HSV encephalitis and other serious manifestations (eg, neonatal HSV infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/52\">",
"     52",
"    </a>",
"    ]. Clinicians should check the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm\">",
"     FDA&rsquo;s website",
"    </a>",
"    for information about the availability of IV acyclovir. If IV acyclovir is not available, an alternative IV regimen can be used. Specific recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"     \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507972#H72507972\">",
"     \"Acyclovir: An overview\", section on 'Herpes simplex encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    was shown to be the treatment of choice for the reduction of mortality and morbidity from HSV encephalitis in the mid-1980s. A series of trials compared its efficacy with vidarabine, which had earlier been shown to be better than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who underwent brain biopsy for presumptive HSV encephalitis were randomly assigned to treatment with either vidarabine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      for ten days. One-third of the patients had biopsy-proven disease. Mortality was significantly reduced in the acyclovir-treated patients (28 percent versus 54 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, 127 patients with suspected HSV encephalitis were randomized to a 10-day course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      versus vidarabine [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/55\">",
"       55",
"      </a>",
"      ]. The diagnosis of HSV encephalitis was verified by brain biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antibody responses in serum and CSF in 53 patients. Mortality was significantly decreased in the acyclovir group compared to the vidarabine group (19 percent versus 50 percent).",
"     </li>",
"     <li>",
"      In both of the above studies, six-month assessments confirmed that functional status was significantly better in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      -treated patients compared to those assigned to the vidarabine arm [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/53,55\">",
"       53,55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is only effective in halting viral replication, it should be given early, to prevent extensive replication and subsequent CNS damage. Early treatment is defined as any one of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Before loss of consciousness",
"     </li>",
"     <li>",
"      Within 24 hours of the onset of symptoms",
"     </li>",
"     <li>",
"      Glasgow Coma Scale score of 9 to 15",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early, aggressive antiviral therapy can prevent mortality and limit the severity of chronic postencephalitic behavioral and cognitive impairments [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/23\">",
"     23",
"    </a>",
"    ]. Suspected cases of HSV encephalitis should receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV Q 8h) with dose adjustment for renal insufficiency. The mechanism of action and toxicity profile of acyclovir are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    must be infused slowly and with a fluid bolus to prevent crystalluria and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ]. Neurologic toxicity has only been observed at extremely high doses (&gt;10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 hours) or in cases of renal failure without dose adjustment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the original trials cited above used only 10 days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , the duration of treatment of HSV encephalitis in immunocompetent patients should be 14 to 21 days since shorter time periods have been associated with occasional relapse with acyclovir-sensitive HSV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/36,57,58\">",
"     36,57,58",
"    </a>",
"    ]. This phenomenon has been mainly observed in children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The low toxicity profile of the drug makes longer duration of therapy possible.",
"   </p>",
"   <p>",
"    One study evaluated the pharmacokinetics of orally administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (1 g orally three times daily for 21 days) in four patients with HSV encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/59\">",
"     59",
"    </a>",
"    ]. The patients achieved and maintained therapeutic concentrations of valacyclovir in the CSF for the duration of therapy, although the CSF concentrations dropped over time, likely reflecting a reduction in blood-brain barrier permeability with healing of the infection. Further study is necessary before valacyclovir can be recommended for HSV encephalitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DISCONTINUATION OF THERAPY BASED ON PCR RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a low prior probability of HSV encephalitis (normal neuroimaging, &lt;5",
"    <span class=\"nowrap\">",
"     cells/mm2",
"    </span>",
"    in CSF, normal mental status), a negative CSF HSV PCR result reduces the likelihood of disease to &lt;1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/43\">",
"     43",
"    </a>",
"    ]. Antiviral therapy may thus be discontinued if a negative CSF HSV PCR result is obtained after 72 hours following onset of neurological signs and symptoms.",
"   </p>",
"   <p>",
"    In contrast, in patients with a high prior probability of HSV encephalitis (suggestive neuroimaging findings, CSF pleocytosis, positive EEG findings, or seizures), a negative PCR result reduces the disease likelihood to approximately 5 percent. In addition, clinicians must consider alternative reasons for a false-negative CSF PCR result, including early testing after the onset of symptoms, antiviral therapy, or presence of PCR inhibitors (eg, hemoglobin degradation products in bloody CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated, the fatality in herpes encephalitis can approach 70 percent and most of the survivors have serious neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Survivors can also have significant neuropsychiatric and neurobehavioral issues [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even with appropriate diagnosis and treatment, mortality may still be as high as 20 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/2,53,55\">",
"     2,53,55",
"    </a>",
"    ]. A large retrospective multicenter study of 93 adult patients with HSV encephalitis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    assessed outcome and prognostic factors for morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/61\">",
"     61",
"    </a>",
"    ]. Among 85 patients assessed at six months, 13 died (15 percent) and 17 (20 percent) had a severe disability. A multivariate analysis identified two factors associated with poor outcome: a Simplified Acute Physiology Score &gt;27 at admission and a delay of greater than two days between presentation to the hospital and initiation of acyclovir therapy.",
"   </p>",
"   <p>",
"    Survivors may have significant long-term morbidity after HSV encephalitis. Severe behavioral abnormalities, anterograde amnesia, features of KBS, and severe cognitive impairment are potentially chronic aspects of the postencephalitic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/23,62\">",
"     23,62",
"    </a>",
"    ]. Long-term follow-up of treated patients may show residual neurologic deficits on either clinical or formal neurologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/60\">",
"     60",
"    </a>",
"    ]. The most common residua are dysnomia and impaired new learning for both verbal and visual material, despite normal performances on a standard mental status examination [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/56\">",
"     56",
"    </a>",
"    ]. One study from Sweden highlighted that rehospitalization was frequent among 236 survivors with confirmed HSV encephalitis (occurring in 87 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1001/abstract/6\">",
"     6",
"    </a>",
"    ]. Reasons for hospital admission included seizure disorder, neuropsychiatric illness, or thromboembolic phenomena.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/50/18209?source=see_link\">",
"       \"Patient information: Encephalitis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Herpes encephalitis is the most common cause of fatal sporadic encephalitis in the United States and involves all age groups. In nearly all cases of herpes encephalitis beyond the neonatal period, the etiologic agent is herpes simplex virus type 1 (HSV-1). In neonates, herpes encephalitis may be caused by either HSV-1 or HSV-2. The clinical syndrome is often characterized by the rapid onset of fever, headache, seizures, focal neurologic signs, and impaired consciousness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend lumbar puncture for CSF analysis and PCR testing for HSV in any patient with encephalitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also recommend brain CT imaging to assess signs of temporal lobe involvement, which would support the diagnosis. Absence of this finding does not alter decisions regarding empiric therapy. CT imaging would also eliminate other alternative causes of mental status changes, such as brain abscess. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend brain biopsy if the patient clinically deteriorates on appropriate therapy and PCR testing is negative for HSV. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Brain biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with suspected HSV encephalitis receive empiric therapy, since delays of treatment have led to significant neurologic sequelae (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours) for empiric therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Treatment duration is 14 to 21 days. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As of November 2012, there is a national shortage of IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      in the United States. If IV acyclovir is not available, an alternative IV regimen can be used. Specific recommendations are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"       \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/1\">",
"      Hanley DF, Johnson RT, Whitley RJ. Yes, brain biopsy should be a prerequisite for herpes simplex encephalitis treatment. Arch Neurol 1987; 44:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/2\">",
"      Levitz RE. Herpes simplex encephalitis: a review. Heart Lung 1998; 27:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/3\">",
"      Whitley RJ. Viral encephalitis. N Engl J Med 1990; 323:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/4\">",
"      Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. Semin Pediatr Infect Dis 2005; 16:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/5\">",
"      Huppatz C, Durrheim DN, Levi C, et al. Etiology of encephalitis in Australia, 1990-2007. Emerg Infect Dis 2009; 15:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/6\">",
"      Hjalmarsson A, Blomqvist P, Sk&ouml;ldenberg B. Herpes simplex encephalitis in Sweden, 1990-2001: incidence, morbidity, and mortality. Clin Infect Dis 2007; 45:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/7\">",
"      Corey L, Whitley RJ, Stone EF, Mohan K. Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome. Lancet 1988; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/8\">",
"      Hudson SJ, Dix RD, Streilein JW. Induction of encephalitis in SJL mice by intranasal infection with herpes simplex virus type 1: a possible model of herpes simplex encephalitis in humans. J Infect Dis 1991; 163:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/9\">",
"      Barnett EM, Jacobsen G, Evans G, et al. Herpes simplex encephalitis in the temporal cortex and limbic system after trigeminal nerve inoculation. J Infect Dis 1994; 169:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/10\">",
"      Stanberry LR, Floyd-Reising SA, Connelly BL, et al. Herpes simplex viremia: report of eight pediatric cases and review of the literature. Clin Infect Dis 1994; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/11\">",
"      Harel L, Smetana Z, Prais D, et al. Presence of viremia in patients with primary herpetic gingivostomatitis. Clin Infect Dis 2004; 39:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/12\">",
"      Stroop WG, Schaefer DC. Production of encephalitis restricted to the temporal lobes by experimental reactivation of herpes simplex virus. J Infect Dis 1986; 153:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/13\">",
"      Bradford RD, Pettit AC, Wright PW, et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis 2009; 49:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/14\">",
"      Pepose JS, Hilborne LH, Cancilla PA, Foos RY. Concurrent herpes simplex and cytomegalovirus retinitis and encephalitis in the acquired immune deficiency syndrome (AIDS). Ophthalmology 1984; 91:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/15\">",
"      Wildemann B, Ehrhart K, Storch-Hagenlocher B, et al. Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis. Neurology 1997; 48:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/16\">",
"      Hudson SJ, Streilein JW. Functional cytotoxic T cells are associated with focal lesions in the brains of SJL mice with experimental herpes simplex encephalitis. J Immunol 1994; 152:5540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/17\">",
"      Koprowski H, Zheng YM, Heber-Katz E, et al. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci U S A 1993; 90:3024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/18\">",
"      Ikemoto K, Pollard RB, Fukumoto T, et al. Small amounts of exogenous IL-4 increase the severity of encephalitis induced in mice by the intranasal infection of herpes simplex virus type 1. J Immunol 1995; 155:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/19\">",
"      Hayashi K, Yanagi K, Takagi S. Detection of herpes simplex virus type 1-IgM immune complexes in the brain of a patient with prolonged herpes encephalitis. J Infect Dis 1986; 153:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/20\">",
"      Pr&uuml;ss H, Finke C, H&ouml;ltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/21\">",
"      Whitley RJ, Cobbs CG, Alford CA Jr, et al. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA 1989; 262:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/22\">",
"      Tyler KL, Tedder DG, Yamamoto LJ, et al. Recurrent brainstem encephalitis associated with herpes simplex virus type 1 DNA in cerebrospinal fluid. Neurology 1995; 45:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/23\">",
"      Hart RP, Kwentus JA, Frazier RB, Hormel TL. Natural history of Kl&uuml;ver-Bucy syndrome after treated herpes encephalitis. South Med J 1986; 79:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/24\">",
"      Fisher CM. Hypomanic symptoms caused by herpes simplex encephalitis. Neurology 1996; 47:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/25\">",
"      Nahmias AJ, Whitley RJ, Visintine AN, et al. Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis 1982; 145:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/26\">",
"      Razavi B, Razavi M. Herpes simplex encephalitis--an atypical case. Infection 2001; 29:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/27\">",
"      Wasay M, Mekan SF, Khelaeni B, et al. Extra temporal involvement in herpes simplex encephalitis. Eur J Neurol 2005; 12:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/28\">",
"      Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1995; 171:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/29\">",
"      Domingues RB, Fink MC, Tsanaclis AM, et al. Diagnosis of herpes simplex encephalitis by magnetic resonance imaging and polymerase chain reaction assay of cerebrospinal fluid. J Neurol Sci 1998; 157:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/30\">",
"      McCabe K, Tyler K, Tanabe J. Diffusion-weighted MRI abnormalities as a clue to the diagnosis of herpes simplex encephalitis. Neurology 2003; 61:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/31\">",
"      Hatipoglu HG, Sakman B, Yuksel E. Magnetic resonance and diffusion-weighted imaging findings of herpes simplex encephalitis. Herpes 2008; 15:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/32\">",
"      Heiner L, Demaerel P. Diffusion-weighted MR imaging findings in a patient with herpes simplex encephalitis. Eur J Radiol 2003; 45:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/33\">",
"      K&uuml;ker W, N&auml;gele T, Schmidt F, et al. Diffusion-weighted MRI in herpes simplex encephalitis: a report of three cases. Neuroradiology 2004; 46:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/34\">",
"      Launes J, Nikkinen P, Lindroth L, et al. Diagnosis of acute herpes simplex encephalitis by brain perfusion single photon emission computed tomography. Lancet 1988; 1:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/35\">",
"      Rose JW, Stroop WG, Matsuo F, Henkel J. Atypical herpes simplex encephalitis: clinical, virologic, and neuropathologic evaluation. Neurology 1992; 42:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/36\">",
"      VanLandingham KE, Marsteller HB, Ross GW, Hayden FG. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA 1988; 259:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/37\">",
"      Rowley AH, Whitley RJ, Lakeman FD, Wolinsky SM. Rapid detection of herpes-simplex-virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis. Lancet 1990; 335:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/38\">",
"      Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. Lancet 2002; 359:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/39\">",
"      Marano E, Briganti F, Tortora F, et al. Neurosyphilis with complex partial status epilepticus and mesiotemporal MRI abnormalities mimicking herpes simplex encephalitis. J Neurol Neurosurg Psychiatry 2004; 75:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/40\">",
"      Szilak I, Marty F, Helft J, Soeiro R. Neurosyphilis presenting as herpes simplex encephalitis. Clin Infect Dis 2001; 32:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/41\">",
"      Giglio P, Bakshi R, Block S, et al. Primary central nervous system lymphoma masquerading as herpes encephalitis: clinical, magnetic resonance imaging, and pathologic findings. Am J Med Sci 2002; 323:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/42\">",
"      Hasegawa T, Kanno S, Kato M, et al. Neuro-Beh&ccedil;et's disease presenting initially as mesiotemporal lesions mimicking herpes simplex encephalitis. Eur J Neurol 2005; 12:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/43\">",
"      Tyler KL. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's. Herpes 2004; 11 Suppl 2:57A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/44\">",
"      Boivin G. Diagnosis of herpesvirus infections of the central nervous system. Herpes 2004; 11 Suppl 2:48A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/45\">",
"      DeBiasi RL, Kleinschmidt-DeMasters BK, Weinberg A, Tyler KL. Use of PCR for the diagnosis of herpesvirus infections of the central nervous system. J Clin Virol 2002; 25 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/46\">",
"      Soong SJ, Watson NE, Caddell GR, et al. Use of brain biopsy for diagnostic evaluation of patients with suspected herpes simplex encephalitis: a statistical model and its clinical implications. NIAID Collaborative Antiviral Study Group. J Infect Dis 1991; 163:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/47\">",
"      Burns J, Redfern DR, Esiri MM, McGee JO. Human and viral gene detection in routine paraffin embedded tissue by in situ hybridisation with biotinylated probes: viral localisation in herpes encephalitis. J Clin Pathol 1986; 39:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/48\">",
"      Kahlon J, Chatterjee S, Lakeman FD, et al. Detection of antibodies to herpes simplex virus in the cerebrospinal fluid of patients with herpes simplex encephalitis. J Infect Dis 1987; 155:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/49\">",
"      Lakeman FD, Koga J, Whitley RJ. Detection of antigen to herpes simplex virus in cerebrospinal fluid from patients with herpes simplex encephalitis. J Infect Dis 1987; 155:1172.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. file://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Current Drug Shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online. Antiviral recommendations for herpes simplex virus (HSV) and varicella zoster virus (vzv) infections in hospitalized pediatric patients during the intravenous acyclovir shortage. file://aapredbook.aappublications.org/site/news/acyclovir.xhtml (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/53\">",
"      Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/54\">",
"      Jeffries DJ. Clinical use of acyclovir. Br Med J (Clin Res Ed) 1985; 290:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/55\">",
"      Sk&ouml;ldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet 1984; 2:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/56\">",
"      Gordon B, Selnes OA, Hart J Jr, et al. Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol 1990; 47:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/57\">",
"      Valencia I, Miles DK, Melvin J, et al. Relapse of herpes encephalitis after acyclovir therapy: report of two new cases and review of the literature. Neuropediatrics 2004; 35:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/58\">",
"      De Ti&egrave;ge X, Rozenberg F, Des Portes V, et al. Herpes simplex encephalitis relapses in children: differentiation of two neurologic entities. Neurology 2003; 61:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/59\">",
"      Pouplin T, Pouplin JN, Van Toi P, et al. Valacyclovir for herpes simplex encephalitis. Antimicrob Agents Chemother 2011; 55:3624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/60\">",
"      Arciniegas DB, Anderson CA. Viral encephalitis: neuropsychiatric and neurobehavioral aspects. Curr Psychiatry Rep 2004; 6:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/61\">",
"      Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis 2002; 35:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1001/abstract/62\">",
"      Grydeland H, Walhovd KB, Westlye LT, et al. Amnesia following herpes simplex encephalitis: diffusion-tensor imaging uncovers reduced integrity of normal-appearing white matter. Radiology 2010; 257:774.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8278 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-E31ECE9AB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_1001=[""].join("\n");
var outline_f0_62_1001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Routes of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Host susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tissue injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electroencephalogram (EEG)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Brain biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CSF antigen and antibody determinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Viral culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DISCONTINUATION OF THERAPY BASED ON PCR RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8278\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8278|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/63/23545\" title=\"diagnostic image 1\">",
"      MRI HSV encephalitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34789?source=related_link\">",
"      PCR testing for the diagnosis of herpes simplex virus in patients with encephalitis or meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/50/18209?source=related_link\">",
"      Patient information: Encephalitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_62_1002="Management of patent ductus arteriosus in premature infants";
var content_f0_62_1002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of patent ductus arteriosus in premature infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/1002/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/1002/contributors\">",
"     Joseph B Philips III, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/1002/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/1002/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/1002/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/1002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/1002/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/62/1002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15148221\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During fetal life, the ductus arteriosus (DA) diverts blood from the pulmonary artery into the aorta, thereby bypassing the lungs (",
"    <a class=\"graphic graphic_figure graphicRef65828 \" href=\"UTD.htm?10/31/10739\">",
"     figure 1",
"    </a>",
"    ). After birth, the DA undergoes active constriction and eventual obliteration. A patent ductus arteriosus (PDA) occurs when the DA fails to completely close after delivery.",
"   </p>",
"   <p>",
"    Preterm infants with moderate to large left-to-right shunts have a greater mortality rate than those without a PDA. They also have an increased risk of pulmonary edema and hemorrhage, bronchopulmonary dysplasia, and a decrease in perfusion and oxygen delivery to end-organs. As a result, management of preterm infants with clinically significant PDAs has been focused on PDA closure and prevention. The management of PDA in preterm infants will be reviewed here. The pathophysiology, clinical manifestations, and diagnosis of PDA in preterm infants are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17050060\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last several decades, research efforts have focused on preventing and closing patent ductus arteriosus&rsquo; (PDAs) in premature infants. However, current practice is focused on PDA closure as the benefit of preventive measures to reduce the incidence of PDA appears to be outweighed by the adverse effects of prophylactic therapy. (See",
"    <a class=\"local\" href=\"#H1214679\">",
"     'Prophylactic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The current management of PDA in premature infants includes three different approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conservative management with supportive therapy alone",
"     </li>",
"     <li>",
"      Pharmacologic closure using cyclooxygenase inhibitors (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Surgical ligation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The support for either medical or surgical closure is based on data from studies in the 1980s and 1990s that demonstrated PDAs in very low birth weight (VLBW) infants (birth weight below 1500) were associated with pulmonary edema, bronchopulmonary dysplasia, intraventricular hemorrhage, and necrotizing enterocolitis. As a result, many preterm infants with a gestational age less than 28 weeks have received either medical or surgical therapy for PDA closure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, neonatal practice is continuously changing, and the increasing use of antenatal glucocorticoid therapy, postnatal surfactant therapy, and the adoption of lower targets of oxygen saturation may have affected both the incidence and impact of a clinically significant PDA shunt. Data are not available regarding the natural course of an untreated PDA in neonatal centers where these practices have become standard of care. In addition, there are no randomized controlled trials comparing outcomes of the three different approaches. Therefore, it remains unclear which approach is most advantageous for premature infants and whether clinical parameters or settings may favor one approach over another. This uncertainty has lead to variation in the management of PDA in preterm infants not only amongst different neonatal intensive care units (NICU), but often within a single NICU.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214585\">",
"    <span class=\"h1\">",
"     SUPPORTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All neonates with patent ductus arteriosus (PDA) should receive the following supportive care regardless of the approach chosen to manage their PDA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A neutral thermal environment and adequate oxygenation that minimize demands on left ventricular (LV) function.",
"     </li>",
"     <li>",
"      The use of positive end-expiratory pressure (PEEP) to improve gas exchange in infants with respiratory compromise. In a study in preterm lambs, PEEP decreased left-to-right ductal flow and increased systemic blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maintenance of the hematocrit at 35 to 40 percent may increase pulmonary vascular resistance and reduce left-to-right shunting, although no trials have evaluated the effect of blood transfusion on PDA closure [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1238242703\">",
"    <span class=\"h2\">",
"     Avoidance of loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend routine use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    or any other loop diuretic, which stimulates renal synthesis of prostaglandin E",
"    <sub>",
"     2",
"    </sub>",
"    , a potent vasodilator that maintains ductus arteriosus (DA) patency. In a trial of diuretic therapy in premature infants with respiratory distress syndrome, a PDA occurred more frequently in infants treated with furosemide compared with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/27/20919?source=see_link\">",
"     chlorothiazide",
"    </a>",
"    (55 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/3\">",
"     3",
"    </a>",
"    ]. In a retrospective study of preterm infants below 32 weeks gestation, furosemide was associated with an increase in serum creatinine and hyponatremia, but not an increase urine output [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/4\">",
"     4",
"    </a>",
"    ]. We recommend the use of thiazide diuretics (eg, chlorothiazide) whenever diuretic therapy is being considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1238242696\">",
"    <span class=\"h2\">",
"     Fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid restriction is widely used in management of neonatal PDA, although evidence for efficacy is lacking. As an example, in a small prospective study of 18 preterm infants (between 24 weeks and &lt;32 weeks) with significant PDAs whose fluid intake was decreased from 145 to 108",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day, there were no changes in respiratory or hemodynamic parameters including fraction of inspired oxygen, blood gas values, ductus arteriosus diameter, left",
"    <span class=\"nowrap\">",
"     atrial/aortic",
"    </span>",
"    root ratio, and blood flow-velocities in the PDA, left pulmonary artery, and aorta. However, decreases in systemic blood pressure, blood flow in the superior vena cava, and mean blood flow-velocity in the superior mesenteric artery were observed. These results may be limited as the study duration was only 24 hours long, which may have been too short of a time period to show benefit or harm.",
"   </p>",
"   <p>",
"    In contrast, excessive fluid administration (greater than 170",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day) is associated with an increased incidence of PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/5\">",
"     5",
"    </a>",
"    ]. Moderate daily fluid restriction between 110 and 130",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    seems prudent to limit pulmonary edema in infants with hemodynamically significant PDA, especially in those with severe respiratory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17050117\">",
"    <span class=\"h1\">",
"     CYCLOOXYGENASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandin E",
"    <sub>",
"     2",
"    </sub>",
"    (PGE",
"    <sub>",
"     2",
"    </sub>",
"    ) is a vasodilator that promotes ductal patency. In the 1970s, two studies demonstrated pharmacologic closure of patent ductus arteriosus (PDA) within 24 hours with the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    , an inhibitor of cyclooxygenase (COX), the pivotal enzyme in the synthesis of PGE",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Currently, the two cyclooxygenase inhibitors used to medically close PDAs are indomethacin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The efficacy of these two COX inhibitors in PDA closure was illustrated by a systematic review of the literature that included 19 randomized trials that compared the intravenous administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    to placebo and to each other [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/8\">",
"     8",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       Indomethacin",
"      </a>",
"      was twice as likely to close a PDA as placebo (pooled RR 2.39, 95% CI 2.05-2.78). There were no differences in the risk of necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), chronic lung disease (CLD), and death between indomethacin and placebo.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      was also twice as likely to close a PDA as placebo (pooled RR 2.4, 95% CI 2.03-2.84). There were no differences in the risk of NEC, IVH, and death between",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      and placebo. However, there was a trend towards an increased risk of CLD associated with ibuprofen compared with placebo (pooled RR 1.29, 95% CI 0.99-1.7).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       Indomethacin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      were equally effective in PDA closure (pooled RR 1.0, 95% CI 0.93-1.08). There were no differences in the risk of NEC, IVH, and death between the two COX inhibitors. However, there was an increased risk of CLD associated with ibuprofen compared with indomethacin (pooled RR 1.28, 95% CI 1.03-1.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major limitation of this study was the high level of heterogeneity in outcome effect, especially regarding CLD. This may be due to the use of different definitions for CLD or variation in baseline risk of respiratory morbidity among studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214592\">",
"    <span class=\"h2\">",
"     Indomethacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been clearly established both by observational studies and randomized trials that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    increases the rate of PDA closure within 24 hours of its administration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ]. Less clearly established are the optimal timing, dose, and duration of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214606\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    vary among premature infants, and serum half-life decreases with postnatal age. In addition, ductal constriction and adverse effects of indomethacin do not correlate strongly with plasma concentrations. Although some studies suggest that obtaining indomethacin concentrations to adjust dosing may improve the rate of ductal closure, these measurements are not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. More than one dose is typically required for sustained constriction. Based on these data, indomethacin is usually given intravenously as multiple doses that range between 0.1 and 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose administered at 12-to 24-hour intervals. In our practice, we give three doses (0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) at 12-hour intervals.",
"   </p>",
"   <p>",
"    Others recommend dosing based on age as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infants less than 48 hours of age &ndash;",
"      <span class=\"nowrap\">",
"       0.1mg/kg",
"      </span>",
"      per dose",
"     </li>",
"     <li>",
"      Infants greater than 48 hours but less than 7 days of age &ndash; 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose",
"     </li>",
"     <li>",
"      Infants more than one week of age &ndash; 0.25",
"      <span class=\"nowrap\">",
"       mg/kg/dose",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results from one trial support a strategy of discontinuing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    if there is an adequate response based on functional echocardiographic findings following an initial dose (0.1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/14\">",
"     14",
"    </a>",
"    ]. In this study, there were no differences in the rate of PDA closure, reopening, and the need for surgical ligation between the echocardiogram-managed group and controls treated in a standard two or more doses regimen. The use of echocardiogram to determine initial response could potentially reduce the amount of indomethacin exposure and its potential adverse effects. However, there was a trend towards a higher incidence of intraventricular hemorrhage in the echocardiogram-managed group, although the number of patients was too small to accurately assess neurologic outcome. Additional trials are needed to validate this approach before it can be adopted as a treatment option in preterm infants with PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214613\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    suppresses prostaglandin synthesis only transiently, a prolonged course of indomethacin has been suggested to sustain ductal constriction while anatomic remodeling occurs. However, a systematic review of five randomized controlled trials showed that a prolonged (four or more doses) administration of indomethacin compared with a short course of therapy (three or less doses) did not yield statistically significant differences in PDA closure, retreatment, re-opening, or surgical ligation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, prolonged therapy appeared to be associated with an increased risk of NEC (RR 1.87, 95% CI 1.07-3.27) and a decreased risk of renal function impairment as demonstrated by a lower proportion of infants with diminished urine output (RR 0.27, 95% CI 0.13-0.6) and elevated serum creatinine (RR 0.51, 95% CI 0.33-0.77) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/15\">",
"     15",
"    </a>",
"    ]. Based upon this analysis, a prolonged course of indomethacin cannot be recommended for the routine treatment of PDA in premature infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214627\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    reduces cerebral, gastrointestinal, and renal blood flow. Preterm infants often develop reduced urine output that is transient and does not usually lead to permanent renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/16\">",
"     16",
"    </a>",
"    ]. Indomethacin may actually enhance renal function that is compromised by a symptomatic PDA. Dopamine may improve indomethacin-related tubular dysfunction and result in higher urine volume and fractional excretion of sodium [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    is of little benefit in reducing renal toxicity and is contraindicated when dehydration is present [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    has been associated with isolated gastrointestinal perforation; although, as noted above, the risk of NEC is reduced by early symptomatic treatment of PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    also causes platelet dysfunction, which may promote bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17050341\">",
"    <span class=\"h3\">",
"     Pulmonary hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    is associated with a decrease in pulmonary hemorrhage, mainly through PDA closure in infants with birth weights below 1000 g [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/19\">",
"     19",
"    </a>",
"    ]. The mechanism of this reduction in pulmonary hemorrhage is thought to be reduced pulmonary overcirculation resulting from ductal constriction. This leads to reduced capillary engorgement in the lungs and thereby reduces the risk of hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11727469\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    is contraindicated in infants with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proven or suspected infection that is untreated",
"     </li>",
"     <li>",
"      Active bleeding, especially those with active intracranial hemorrhage or gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coagulation defects",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis (NEC) or suspected of having NEC",
"     </li>",
"     <li>",
"      Significant impairment of renal function",
"     </li>",
"     <li>",
"      Congenital heart disease in which patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow (eg, pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214641\">",
"    <span class=\"h2\">",
"     Ibuprofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of a PDA with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is comparable to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    . Similar adverse events (eg, isolated gastrointestinal perforation and renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]) have been reported.",
"   </p>",
"   <p>",
"    In systematic reviews,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    was as effective as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    in closing PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In addition, ibuprofen was associated with a lower risk of NEC, and transient renal insufficiency. However, there have been case reports of fatal pulmonary hypertension associated with administration of ibuprofen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70091087\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    for PDA closure is an initial dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    followed by two additional doses of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given at 24 hour intervals. Ibuprofen is typically given as an intravenous preparation in developed countries. However, the intravenous preparation is expensive and many nurseries in developing countries are using oral ibuprofen for PDA closure.",
"   </p>",
"   <p>",
"    In one randomized Turkish trial of 102 very low birth weight (VLBW) infants (birth weight below 1500), oral administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    was more effective than intravenous administration for PDA closure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/26\">",
"     26",
"    </a>",
"    ]. Oral ibuprofen appeared to be associated with fewer side effects, although the study size was too small to detect significant differences in the rate of adverse events. In a trial of more premature infants (extremely low birth weight infants with birth weights below 1000 g) from the same institution, oral ibuprofen was equally effective as the intravenous preparation for PDA closure (83 versus 62 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, the likelihood of receiving a second course of treatment was similar for oral (11 of 36 patients) and intravenous (15 of 34 patients) ibuprofen.",
"   </p>",
"   <p>",
"    Further trials are needed to confirm that oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is as effective and safe as intravenous ibuprofen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11727476\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contraindications for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    are similar to those for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    . However, we have had notable success in treating patients with renal failure and large PDAs with use of ibuprofen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11727483\">",
"    <span class=\"h2\">",
"     Indomethacin versus ibuprofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;As demonstrated by the above meta-analysis, there is little reason to prefer one drug over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/8\">",
"     8",
"    </a>",
"    ]. As a result, in most instances, individual, institutional, and economic preferences dictate the choice of drug. In infants with significant renal compromise,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is the preferred drug.",
"   </p>",
"   <p>",
"    It appears that both agents interfere with the binding of bilirubin to albumin, thus potentially increasing the risk of kernicterus.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    affects bilirubin binding only at plasma concentrations that far exceed those seen clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], whereas an in vitro study reported that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    interferes with binding at serum concentrations achieved by the usual doses of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/30\">",
"     30",
"    </a>",
"    ]. Two retrospective studies also demonstrated that average peak bilirubin levels were higher in patients treated with ibuprofen compared with those treated with indomethacin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. However, in a prospective study of 32 preterm infants with baseline total bilirubin (TB) concentration less than 8.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (150.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    there was no difference in levels of TB and unbound bilirubin between baseline measurements and those measured one and six hours after administration of a standard loading dose of intravenous ibuprofen (10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/32\">",
"     32",
"    </a>",
"    ]. Infants with higher levels of TB were not allowed to participate in this study. As a result, these results do not provide data for patients with levels of TB &gt;8.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (150.5",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20653043\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the optimal timing of COX inhibitor administration for PDA closure are limited and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinical trial that randomly assigned early treatment of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      or initial placebo (expectant) to preterm infants with subtle signs of PDA (murmur, bounding pulse, and metabolic acidosis) reported half of the patients who received placebo did not require any additional medical (open label ibuprofen) or surgical treatment for their PDAs [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/33\">",
"       33",
"      </a>",
"      ]. The median age of ibuprofen treatment was three days in the early treatment group versus 10 days for those who received medical treatment in the initial placebo group. There was no difference between the two groups in the primary outcome of days requiring oxygen supplementation during the first 28 days of life. In addition, there was no difference in the administration of open label ibuprofen, surgical ligation, or mortality. These data support the use of COX inhibitor therapy only in patients with hemodynamically significant PDA (eg, hypotension, pulmonary hemorrhage, or respiratory deterioration). Of note, this study was terminated at two-thirds enrollment because of the recall of intravenous ibuprofen.",
"     </li>",
"     <li>",
"      A meta-analysis demonstrated early (first two or three days after delivery) versus late (7 to 10 days after delivery) administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      in preterm infants with PDAs was associated with shorter duration of mechanical ventilation and decreased risk of bronchopulmonary dysplasia (OR 0.39, 95% CI 0.21-0.76), necrotizing enterocolitis (NEC) (OR 0.24, 95% CI 0.06-0.96), and need for surgical ligation (OR 0.37, 95% CI 0.20-0.68) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, when pharmacologic closure is considered, we suggest administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    in infants with a significant PDA prior to the onset of signs of heart failure. (See",
"    <a class=\"local\" href=\"#H17050762\">",
"     'Our approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266530521\">",
"    <span class=\"h2\">",
"     Failure to respond",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant proportion of patients will fail to respond to an initial dose of cyclooxygenase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Risk factors associated with a persistent PDA include lower gestational age, lack of exposure to antenatal corticosteroid therapy, increased severity of respiratory distress, and intrauterine inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. These factors may be associated with increased cyclooxygenase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest a second course of cyclooxygenase inhibitor therapy is associated with a 40 percent rate of ductal closure in patients who fail to respond to initial therapy as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study, 70 of 160 patients initially treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      had successful ductal closure [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/37\">",
"       37",
"      </a>",
"      ]. In 80 patients who failed to respond, a second course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      resulted in closure in 32 patients (40 percent). The response rate was lower in infants with a gestational age &lt;26 weeks compared to more mature infants for both first (28 versus 64 percent) and second courses of therapy (31 versus 60 percent).",
"     </li>",
"     <li>",
"      In a case series of infants (gestational age &lt;28 weeks) with recurrent PDA after initial",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      treatment, a second course of indomethacin therapy was associated with permanent ductal closure in 14 of 32 infants (44 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third case series of 164 preterm infants, a closure rate between 55 to 60 percent was similar after the first",
"      <span class=\"nowrap\">",
"       (109/164),",
"      </span>",
"      second",
"      <span class=\"nowrap\">",
"       (24/43),",
"      </span>",
"      and third course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/39\">",
"       39",
"      </a>",
"      ]. There were no additional side effects noted after multiple courses of ibuprofen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data and the author&rsquo;s clinical experience, administration of a second dose of cyclooxygenase inhibitor is reasonable in infants who fail an initial course of therapy. However, if the patient fails to respond to two courses of therapy, additional drug treatment is unlikely, and surgical ligation should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214649\">",
"    <span class=\"h1\">",
"     SURGICAL LIGATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical ligation may be performed if the patient remains symptomatic after one or two courses of COX inhibitor or if COX inhibitor treatment is contraindicated. However, pharmacologic therapy remains the preferred initial treatment because ligation is associated with risks of blood pressure fluctuations, respiratory compromise, infection, intraventricular hemorrhage, chylothorax, recurrent laryngeal nerve paralysis, BPD, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reported that surgical ligation was associated with increases in the blood flow velocity of the middle cerebral, celiac, and superior mesenteric arteries. The change in the cerebral vasculature was attenuated and occurred later than in the splanchnic vasculature (24 versus 3 hours) because of the acute adaptation of increased cerebral vascular tone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/42\">",
"     42",
"    </a>",
"    ]. Video-assisted thoracoscopic PDA ligation, if available, offers a less traumatic alternative to the conventional surgical approach [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214657\">",
"    <span class=\"h1\">",
"     CONSERVATIVE APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that conservative treatment using supportive therapy alone in preterm infants with patent ductus arteriosus (PDA) may be a reasonable option versus medical or surgical treatment as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study, 10 of 30 preterm infants developed significant PDAs (defined as DA diameter &ge;1.4 mm by echocardiography measurement) and were treated with fluid restriction (maximum intake of 130",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per day) and ventilator changes (lowered inspiratory time and increased positive end expiratory pressure) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/44\">",
"       44",
"      </a>",
"      ]. In all patients, the PDA closed without surgical or pharmacologic treatment.",
"     </li>",
"     <li>",
"      In another study of very low birth weight infants (birth weight &le;1500 g), outcome measures were compared between treatment strategies used in two distinct time periods: traditional management of patients consisting of medical (ie, course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      ) and surgical treatment between 2005 and 2007 (era 1), and initial supportive care and observation between 2008 and 2009 (era 2) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/45\">",
"       45",
"      </a>",
"      ]. The use of indomethacin and surgical ligation was decreased in era 2 compared with era 1 (indomethacin [26 versus 79 percent] and ligation [33 versus 45 percent]). There were no differences in the use of supplemental oxygen, nasal continuous positive airway pressure, or mechanical ventilation, or mortality. However, the incidence of bronchopulmonary dysplasia was slightly higher in era 2 compared with era 1 (54 versus 40 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the above results should be interpreted cautiously as the number of patients treated was small and the studies were not prospectively controlled. (See",
"    <a class=\"local\" href=\"#H1214585\">",
"     'Supportive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other experts in the field have also advocated conservative management of PDA in preterm infants based on the evidence that demonstrates a high rate of spontaneous closure and established adverse effects of both pharmacologic and surgical intervention, and the lack of evidence that treatment results in a decrease in neonatal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This was illustrated by a review of pooled data from treatment trials of PDA in preterm infants regardless of methodological quality that were published before 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/47\">",
"     47",
"    </a>",
"    ]. In this analysis, early trials with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    suggested reduced mortality; however, subsequent larger studies that used intravenous indomethacin did not find a decrease in mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214664\">",
"    <span class=\"h1\">",
"     COMPARISON OF MANAGEMENT APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have not been large randomized controlled trials comparing the different approaches of managing patent ductus arteriosus (PDA) in preterm infants.",
"   </p>",
"   <p>",
"    Observational data are available, but often the treatment groups differ in gestational age, birth weight, and severity of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. This was illustrated in a study that evaluated 18-month outcome based on the management of PDA in infants with birth weights below 1000 g from the National Institute of Child Health and Human Development Neonatal Research Network Generic Data Base [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/49\">",
"     49",
"    </a>",
"    ]. This study included 403 infants who were treated conservatively, 1525 treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    alone, 135 with primary surgery, and 775 who received indomethacin initially followed by surgery. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants who underwent either primary or secondary surgical closure had lower gestational age, birth weight, and Apgar scores but were less likely to be small for gestational age.",
"     </li>",
"     <li>",
"      There were no differences in the measured demographics between infants treated conservatively and those who only received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      There also were no differences between the conservatively and medically managed groups in mortality, neurodevelopmental outcome at 18 months, the composite outcome of morality and neurodevelopmental outcome, or the risk of BPD or NEC.",
"     </li>",
"     <li>",
"      There were no differences between the primary or secondary surgical groups, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      groups in the composite outcome of mortality and neurodevelopmental outcome or rate of NEC. Patients who underwent secondary surgical closure compared to those treated with indomethacin alone were more likely to have BPD and neurodevelopmental impairment but had a better survival rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The study design, however, has a bias for increased survival in patients treated surgically because surgical deaths were only counted after the procedure, whereas deaths in the medically treated group were reported any time after the diagnosis of PDA.",
"   </p>",
"   <p>",
"    In an observational study from the Canadian Neonatal Network of 3556 infants with PDA, 2026 were treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    alone (57 percent), 626 with both surgical ligation and indomethacin (18 percent), 577 with conservative treatment (16 percent), and 327 with surgical ligation alone (9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/51\">",
"     51",
"    </a>",
"    ]. Multivariate analysis showed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher mortality and morbidity (ie, BPD, grade 3 or 4 intraventricular hemorrhage [IVH], and stages 3 to 5 retinopathy of prematurity [ROP]) for patients treated with surgical ligation, irrespective of previous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      therapy, compared with infants treated conservatively or with indomethacin alone.",
"     </li>",
"     <li>",
"      There were no differences in mortality or morbidity between the groups who were treated conservatively or with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large randomized controlled trials are required to truly compare the different treatment approaches in regards to mortality and complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214679\">",
"    <span class=\"h1\">",
"     PROPHYLACTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the use of prophylactic cyclooxygenase (COX) inhibitors had been proposed to reduce the incidence of patent ductus arteriosus (PDA) and improve neonatal outcome, prophylactic COX inhibitors appear not to be more effective at improving mortality, pulmonary outcome, or reducing the risk of NEC than early treatment of a symptomatic PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, prophylactic treatment of infants that do not develop symptomatic PDA may actually increase the risk of BPD as illustrated in the Trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    Prophylaxis in Preterms (TIPP trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/53\">",
"     53",
"    </a>",
"    ]. In this study, 999 preterm infants (birthweight 500 to 999 g) were randomly assigned to indomethacin prophylaxis or placebo at six hours of life. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      had a significant reduction in the incidence of PDA (21 versus 49 percent with placebo).",
"     </li>",
"     <li>",
"      Infants who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      had a similar incidence of BPD overall (45 versus 43 percent). However, among the subgroup of infants who did not develop PDA, indomethacin was associated with a higher incidence of BPD (43 versus 30 percent), a greater requirement for oxygen supplementation, and less weight loss. The last two findings may have resulted from a decrease in urine output with indomethacin leading to fluid retention, which promoted the development of BPD [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies and a systematic review also showed that prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    versus placebo or no intervention decreased the incidence of PDA at day three of life and the need for therapeutic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. However, the use of ibuprofen was associated with adverse side effects.",
"   </p>",
"   <p>",
"    Based upon these results, prophylactic treatment to reduce the incidence of PDA with COX inhibitors is not recommended because many infants, who would not develop significant PDAs, are unnecessarily exposed to drugs with potentially serious adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17050762\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17050880\">",
"    <span class=\"h2\">",
"     Symptomatic PDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past several decades, management of symptomatic patent ductus arteriosus (PDA) has changed in our neonatal intensive care unit (NICU). Prior to the commercial availability of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    in the 1980s, surgical ligation was performed in preterm infants with PDAs who were dependent on mechanical ventilation. Once indomethacin became available, our management strategy changed to include frequent evaluations to detect PDAs using echocardiograms and to treat all ventilator dependent infants with PDA with indomethacin. Currently, a more moderate approach is used based on initial supportive care and subsequent pharmacologic therapy to close PDAs in infants who remain dependent on mechanical ventilation.",
"   </p>",
"   <p>",
"    As noted above, there are no data to determine the optimal management of PDA in preterm infants. As a result, there is variability in the treatment of PDAs amongst different centers, and among neonatologists at a single NICU including our own institution. The following is a consensus approach to the management of PDA in preterm infants based on the practice of the members of our NICU staff.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial conservative approach with supportive care that includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Daily fluid restriction between 110 and 130",
"      <span class=\"nowrap\">",
"       mL/kg.",
"      </span>",
"     </li>",
"     <li>",
"      Use of permissive hypercapnia, low PaO",
"      <sub>",
"       2",
"      </sub>",
"      targets, and PEEP in infants who are mechanically ventilated to facilitate weaning from the ventilator and extubation, thereby minimizing mechanical lung trauma that increases the risk of bronchopulmonary dysplasia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/27/20919?source=see_link\">",
"       Chlorothiazide",
"      </a>",
"      may be used to treat infants who become fluid-overloaded or with signs of increased interstitial pulmonary fluid.",
"     </li>",
"     <li>",
"      Maintenance of a hematocrit above 35 percent.",
"     </li>",
"     <li>",
"      Neutral thermal environment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A course of a COX inhibitor is given to infants who remain dependent on mechanical ventilation after a few days and have a significant PDA confirmed by echocardiography. We do not routinely measure platelets prior to drug administration but do avoid COX inhibitor use in infants with coagulopathy. We do not use these drugs in patients with NEC because of the risk of decreased blood flow to the bowel. Feedings are withheld at the discretion of the individual attending clinician during drug administration. Urine output is monitored and if oliguria is present, low dose dopamine is administered. (See",
"      <a class=\"local\" href=\"#H1214592\">",
"       'Indomethacin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=see_link&amp;anchor=H10685908#H10685908\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\", section on 'Significant PDA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For infants with clinically significant PDA who also have necrotizing enterocolitis or renal failure or are recovering from intestinal surgery, we will use",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      for pharmacologic PDA closure. (See",
"      <a class=\"local\" href=\"#H1214641\">",
"       'Ibuprofen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A second course of cyclooxygenase inhibitor therapy is given if follow-up echocardiograms show failure of closure and the infant is still ventilator dependent.",
"     </li>",
"     <li>",
"      Surgical ligation of the PDA is rarely performed and is reserved for infants that remain on very high ventilator settings with large PDAs who have failed medical therapy. In our NICU, only 5 of 162 (3 percent) infants less that 28 weeks gestation with PDAs underwent surgical ligation in 2009. Surgery was performed in the infant&rsquo;s room with neonatology staff providing anesthesia and ventilator management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17050887\">",
"    <span class=\"h2\">",
"     Prophylactic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not recommend the use of prophylactic cyclooxygenase inhibitors (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) to reduce the incidence of PDA because many infants, who do not have significant PDAs, are unnecessarily exposed to the adverse effects of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214695\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality is increased in infants whose patent ductus arteriosus (PDA) persists despite attempted closure. In a retrospective study of 252 infants born at or below 28 weeks gestation, survival outcomes were compared among infants who never had a significant PDA, infants whose significant PDA had been successfully closed medically, and those who had a persistent significant PDA after unsuccessful medical closure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/59\">",
"     59",
"    </a>",
"    ]. Infants with a persistent PDA had a fourfold increased risk of death compared to infants who never had a significant PDA. There was no difference in mortality rate between the group of infants who had successful medical closure of their PDA and those who never had a significant PDA.",
"   </p>",
"   <p>",
"    In another retrospective review from a single tertiary center in the United States, 41 VLBW infants with a persistent PDA (failed",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    therapy and not surgically ligated) had an eightfold increased risk of death compared to 260 infants with a closed PDA after adjustment for confounding factors that included perinatal factors, level of maturity, and disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants who receive intervention, it is unclear whether there is a difference in outcome between medical and surgical therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 426 extremely low birth weight infants with PDA from the Trial of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       Indomethacin",
"      </a>",
"      Prophylaxis in Preterms (TIPP), there was a trend toward decreased mortality in patients whose PDAs were surgically closed compared to those who were treated without surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/61\">",
"       61",
"      </a>",
"      ]. However, in surviving infants evaluated at a corrected age of 18 months, neurosensory impairment, bronchopulmonary dysplasia (BPD), and severe retinopathy of prematurity (ROP) were more likely to develop in patients with surgically closed PDA compared to infants who were managed without surgery.",
"      <br/>",
"      <br/>",
"      The observational design of this study makes it difficult to ascertain whether the increased risk of complications are directly related to the surgical procedure (including the effects of anesthesia) or if the surgical intervention included a subset of infants who were more critically ill and, hence, more likely to develop long-term complications. The study design also had a bias for increased survival in patients treated surgically because surgical deaths were only counted after the procedure, whereas deaths in the medically treated group were reported any time after the diagnosis of PDA.",
"      <br/>",
"      <br/>",
"      As a result of these limitations, it is difficult to determine whether medical or surgical treatment for PDA closure is superior in long-term outcome in preterm infants.",
"     </li>",
"     <li>",
"      A retrospective review of 446 infants (gestational age &lt;28 weeks) from a single tertiary center reported the clinical outcome of a standardized protocol utilizing prophylactic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      . After initial prophylactic indomethacin, 15 percent had persistent PDA. Twenty-seven percent developed symptomatic PDA and the attending neonatologist decided upon the subsequent choice of treatment (indomethacin versus surgical ligation). Results, which were adjusted for gestational age, demonstrated no differences in the rates of mortality, necrotizing enterocolitis (NEC), and ROP between patients treated medically or surgically [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/62\">",
"       62",
"      </a>",
"      ] In contrast, increased risk for BPD was associated with surgical ligation.",
"      <br/>",
"      <br/>",
"      A limitation of this study is that the subsequent choice of medical versus surgical treatment was not randomly selected, but was decided upon by the attending neonatologist. In addition, it is unclear whether the exposure to a symptomatic PDA differed between the groups, although there was a difference in the mean duration of exposure to a symptomatic PDA from 0.8 days before the initiation of indomethacin to 1.9 days for surgical closure. It is unclear whether early or late intervention for a persistent PDA affects outcome.",
"     </li>",
"     <li>",
"      A retrospective study suggested that neurodevelopmental outcome was improved when a selective ligation approach was used compared with early ligation for all patients who failed medical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/63\">",
"       63",
"      </a>",
"      ]. Patients who underwent selective ligation were those who failed medical therapy and fulfilled specific criteria including increased ventilator support, inotropic support for hypotension,",
"      <span class=\"nowrap\">",
"       oliguria/renal",
"      </span>",
"      failure,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      failure to gain weight or feeding intolerance.",
"     </li>",
"     <li>",
"      In contrast, another study using a matched case-control analysis reported persistent PDA, defined as greater than three weeks, was associated with increased days of mechanical ventilation, oxygen supplemental therapy, and length of hospital stay, and increased rates of neonatal complications (eg, BPD, ROP, osteopenia, and NEC) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/64\">",
"       64",
"      </a>",
"      ]. This study was limited by the small number of patients with persistent PDA (n = 28 patients), and the characteristics of the PDA are not well documented.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials that compare the clinical outcome of the different management approaches are required to decide upon the most efficacious and safe therapeutic intervention for premature infants with PDA. Until these data are available, we administer pharmacologic treatment to preterm infants with symptomatic PDA in our care as discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/1002/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17050880\">",
"     'Symptomatic PDA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47818026\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm infants with clinically significant patent ductus arteriosus (PDA) have a greater mortality rate than those without a PDA. PDAs also are associated with an increased risk of pulmonary edema and hemorrhage, and bronchopulmonary dysplasia. As a result, management has been focused on PDA closure and prevention. (See",
"    <a class=\"local\" href=\"#H1214695\">",
"     'Outcome'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of PDA includes the following three different approaches. (See",
"      <a class=\"local\" href=\"#H17050060\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Conservative management with supportive care alone (See",
"      <a class=\"local\" href=\"#H1214585\">",
"       'Supportive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic closure using cyclooxygenase inhibitors, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (See",
"      <a class=\"local\" href=\"#H17050117\">",
"       'Cyclooxygenase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical ligation (See",
"      <a class=\"local\" href=\"#H1214649\">",
"       'Surgical ligation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal current management approach is not known as there is a paucity of large randomized controlled trials comparing the three different approaches in the most recent era of neonatal practice. As a result, it remains unclear which approach is most advantageous and whether clinical parameters may favor one approach over another. This uncertainty leads to wide variability in the management of PDA amongst different neonatal intensive care units (NICUs) and even neonatologists who practice in the same NICU. (See",
"      <a class=\"local\" href=\"#H17050060\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our approach to managing preterm infants with symptomatic PDAs, the following therapeutic decisions are based on the severity of respiratory disease and the continued need for mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H17050880\">",
"       'Symptomatic PDA'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend supportive care for all preterm infants with PDAs (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This includes providing a neutral thermal environment, using positive end-expiratory pressure to improve gas exchange, maintaining a hematocrit of 35 to 40 percent, fluid restriction between 110 and 130",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per day, and the use of permissive hypercapnia and low oxygen saturation targets to manage respiratory distress. If diuretic therapy is indicated, we recommend the use of thiazide diuretics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/27/20919?source=see_link\">",
"       chlorothiazide",
"      </a>",
"      ) over loop diuretics such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1214585\">",
"       'Supportive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants with a PDA who remain dependent on mechanical ventilation after two weeks, we suggest a course of cyclooxygenase (COX) inhibitors versus supportive care alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A second course of COX inhibitor is administered if follow-up echocardiograms demonstrate a persistent PDA and the infant remains ventilator dependent. (See",
"      <a class=\"local\" href=\"#H17050117\">",
"       'Cyclooxygenase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that surgical ligation only be performed in infants with large PDAs who remain on high ventilator settings and have failed to respond to COX inhibitors (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We do",
"      <strong>",
"       not",
"      </strong>",
"      recommend the use of prophylactic COX inhibitors to reduce the incidence of PDA, because many infants, who would not develop significant PDAs, are unnecessarily exposed to drugs with potentially serious adverse effects (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1214679\">",
"       'Prophylactic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/1\">",
"      Cotton RB, Lindstrom DP, Kanarek KS, et al. Effect of positive-end-expiratory-pressure on right ventricular output in lambs with hyaline membrane disease. Acta Paediatr Scand 1980; 69:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/2\">",
"      Lister G, Hellenbrand WE, Kleinman CS, Talner NS. Physiologic effects of increasing hemoglobin concentration in left-to-right shunting in infants with ventricular septal defects. N Engl J Med 1982; 306:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/3\">",
"      Green TP, Thompson TR, Johnson DE, Lock JE. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. N Engl J Med 1983; 308:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/4\">",
"      Andriessen P, Struis NC, Niemarkt H, et al. Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus. Acta Paediatr 2009; 98:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/5\">",
"      Stephens BE, Gargus RA, Walden RV, et al. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants. J Perinatol 2008; 28:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/6\">",
"      Friedman WF, Hirschklau MJ, Printz MP, et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 1976; 295:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/7\">",
"      Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976; 295:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/8\">",
"      Jones LJ, Craven PD, Attia J, et al. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011; 96:F45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/9\">",
"      Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983; 102:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/10\">",
"      Noori S, Seri I. Treatment of the patent ductus arteriosus: when, how, and for how long? J Pediatr 2009; 155:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/11\">",
"      Yeh TF, Achanti B, Patel H, Pildes RS. Indomethacin therapy in premature infants with patent ductus arteriosus--determination of therapeutic plasma levels. Dev Pharmacol Ther 1989; 12:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/12\">",
"      Gal P, Ransom JL, Schall S, et al. Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response. J Perinatol 1990; 10:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/13\">",
"      Gal P, Ransom JL, Weaver RL, et al. Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure. Ther Drug Monit 1991; 13:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/14\">",
"      Carmo KB, Evans N, Paradisis M. Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography. J Pediatr 2009; 155:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/15\">",
"      Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2007; :CD003480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/16\">",
"      Davis JM, Hendricks-Munoz KD, Hagberg D, Manning JA. The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus. Dev Pharmacol Ther 1990; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/17\">",
"      Seri I, Tulassay T, Kiszel J, Cs&ouml;m&ouml;r S. The use of dopamine for the prevention of the renal side effects of indomethacin in premature infants with patent ductus arteriosus. Int J Pediatr Nephrol 1984; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/18\">",
"      Brion LP, Campbell DE. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. Cochrane Database Syst Rev 2001; :CD001148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/19\">",
"      Alfaleh K, Smyth JA, Roberts RS, et al. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. Pediatrics 2008; 121:e233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/20\">",
"      Rao R, Bryowsky K, Mao J, et al. Gastrointestinal complications associated with ibuprofen therapy for patent ductus arteriosus. J Perinatol 2011; 31:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/21\">",
"      Bagnoli F, Rossetti A, Messina G, et al. Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med 2013; 26:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/22\">",
"      Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010; :CD003481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/23\">",
"      Neumann R, Schulzke SM, B&uuml;hrer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology 2012; 102:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/24\">",
"      Amendolia B, Lynn M, Bhat V, et al. Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates. Pediatrics 2012; 129:e1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/25\">",
"      Bellini C, Campone F, Serra G. Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. CMAJ 2006; 174:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/26\">",
"      Gokmen T, Erdeve O, Altug N, et al. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr 2011; 158:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/27\">",
"      Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2012; 97:F279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/28\">",
"      Rasmussen LF, Ahlfors CE, Wennberg RP. Displacement of bilirubin from albumin by indomethacin. J Clin Pharmacol 1978; 18:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/29\">",
"      Zecca E, Romagnoli C, De Carolis MP, et al. Does Ibuprofen increase neonatal hyperbilirubinemia? Pediatrics 2009; 124:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/30\">",
"      Ahlfors CE. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr 2004; 144:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/31\">",
"      Rheinlaender C, Helfenstein D, Walch E, et al. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr 2009; 98:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/32\">",
"      Desfrere L, Thibaut C, Kibleur Y, et al. Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants. J Pediatr 2012; 160:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/33\">",
"      Sosenko IR, Fajardo MF, Claure N, Bancalari E. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. J Pediatr 2012; 160:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/34\">",
"      Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 1996; 128:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/35\">",
"      Chorne N, Jegatheesan P, Lin E, et al. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007; 151:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/36\">",
"      Kim ES, Kim EK, Choi CW, et al. Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants. J Pediatr 2010; 157:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/37\">",
"      Richards J, Johnson A, Fox G, Campbell M. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics 2009; 124:e287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/38\">",
"      Keller RL, Clyman RI. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics 2003; 112:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/39\">",
"      van der Lugt NM, Lopriore E, B&ouml;kenkamp R, et al. Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus. Eur J Pediatr 2012; 171:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/40\">",
"      Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med 2000; 343:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/41\">",
"      Clyman R, Cassady G, Kirklin JK, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009; 154:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/42\">",
"      Hoodbhoy SA, Cutting HA, Seddon JA, Campbell ME. Cerebral and splanchnic hemodynamics after duct ligation in very low birth weight infants. J Pediatr 2009; 154:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/43\">",
"      Burke RP, Jacobs JP, Cheng W, et al. Video-assisted thoracoscopic surgery for patent ductus arteriosus in low birth weight neonates and infants. Pediatrics 1999; 104:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/44\">",
"      Vanhaesebrouck S, Zonnenberg I, Vandervoort P, et al. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed 2007; 92:F244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/45\">",
"      Kaempf JW, Wu YX, Kaempf AJ, et al. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants? J Perinatol 2012; 32:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/46\">",
"      Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 2007; 92:F498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/47\">",
"      Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 2010; 30:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/48\">",
"      Benitz WE. Patent ductus arteriosus: to treat or not to treat? Arch Dis Child Fetal Neonatal Ed 2012; 97:F80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/49\">",
"      Madan JC, Kendrick D, Hagadorn JI, et al. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 2009; 123:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/50\">",
"      Alexander F, Chiu L, Kroh M, et al. Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus. J Pediatr Surg 2009; 44:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/51\">",
"      Mirea L, Sankaran K, Seshia M, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr 2012; 161:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/52\">",
"      Cordero L, Nankervis CA, Delooze D, Giannone PJ. Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants? J Perinatol 2007; 27:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/53\">",
"      Schmidt B, Roberts RS, Fanaroff A, et al. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 2006; 148:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/54\">",
"      Bose CL, Laughon M. Treatment to prevent patency of the ductus arteriosus: beneficial or harmful? J Pediatr 2006; 148:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/55\">",
"      Gournay V, Savagner C, Thiriez G, et al. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002; 359:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/56\">",
"      Gournay V, Roze JC, Kuster A, et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/57\">",
"      Van Overmeire B, Allegaert K, Casaer A, et al. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/58\">",
"      Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2011; :CD004213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/59\">",
"      Brooks JM, Travadi JN, Patole SK, et al. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 2005; 90:F235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/60\">",
"      Noori S, McCoy M, Friedlich P, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009; 123:e138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/61\">",
"      Kabra NS, Schmidt B, Roberts RS, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007; 150:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/62\">",
"      Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007; 119:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/63\">",
"      Wickremasinghe AC, Rogers EE, Piecuch RE, et al. Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus. J Pediatr 2012; 161:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/64\">",
"      Salde&ntilde;o YP, Favareto V, Mirpuri J. Prolonged persistent patent ductus arteriosus: potential perdurable anomalies in premature infants. J Perinatol 2012; 32:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/1002/abstract/65\">",
"      Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. J Pediatr 2007; 150:216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15814 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_1002=[""].join("\n");
var outline_f0_62_1002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H47818026\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15148221\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17050060\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1214585\">",
"      SUPPORTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1238242703\">",
"      Avoidance of loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1238242696\">",
"      Fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17050117\">",
"      CYCLOOXYGENASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1214592\">",
"      Indomethacin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1214606\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1214613\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1214627\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17050341\">",
"      - Pulmonary hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11727469\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1214641\">",
"      Ibuprofen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70091087\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11727476\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11727483\">",
"      Indomethacin versus ibuprofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20653043\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266530521\">",
"      Failure to respond",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1214649\">",
"      SURGICAL LIGATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1214657\">",
"      CONSERVATIVE APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1214664\">",
"      COMPARISON OF MANAGEMENT APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1214679\">",
"      PROPHYLACTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17050762\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17050880\">",
"      Symptomatic PDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17050887\">",
"      Prophylactic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1214695\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47818026\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15814|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/31/10739\" title=\"figure 1\">",
"      Pathophysiology PDA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_62_1003="Detection silent ischemia";
var content_f0_62_1003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic modalities for detection and evaluation of silent myocardial ischemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Exercise treadmill test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuous ECG (Holter) monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise myocardial perfusion scintigraphy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radionuclide angiocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharmacologic stress scintigraphy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemodynamic monitoring",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_1003=[""].join("\n");
var outline_f0_62_1003=null;
var title_f0_62_1004="Diastolic vel and preg outcome";
var content_f0_62_1004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absent and reverse end diastolic velocity in the umbilical artery and adverse perinatal outcome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Perinatal outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal mortality",
"       </td>",
"       <td>",
"        45 percent",
"       </td>",
"       <td>",
"        17-100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational age",
"       </td>",
"       <td>",
"        31.6 weeks",
"       </td>",
"       <td>",
"        29-33 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth weight",
"       </td>",
"       <td>",
"        1056 gms",
"       </td>",
"       <td>",
"        910-1481 gms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small for gestational age",
"       </td>",
"       <td>",
"        68 percent",
"       </td>",
"       <td>",
"        53-100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cesarean section for fetal distress",
"       </td>",
"       <td>",
"        73 percent",
"       </td>",
"       <td>",
"        24-100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apgar score at 5 min &lt;7",
"       </td>",
"       <td>",
"        26 percent",
"       </td>",
"       <td>",
"        7-69 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Admission to neonatal intensive care unit",
"       </td>",
"       <td>",
"        84 percent",
"       </td>",
"       <td>",
"        77-97 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital anomalies",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        0-24 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aneuploidy",
"       </td>",
"       <td>",
"        6.4 percent",
"       </td>",
"       <td>",
"        0-18 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Maulik, D. Absent end-diastolic velocity in the umbilical artery and its clinical significance. In: Maulik, D (ed) Doppler ultrasound in obstetrics and gynecology, 1997; 362, New York, Springer Verlag. Copyright &copy; 1997 Springer-Verlag.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_1004=[""].join("\n");
var outline_f0_62_1004=null;
var title_f0_62_1005="Diff diag chronic tubulo neph assoc uroth carc";
var content_f0_62_1005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of some forms of chronic tubulointerstitial nephropathies associated with urothelial carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Aristolochic acid nephropathy",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Analgesic nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Chinese herb nephropathy",
"       </td>",
"       <td class=\"subtitle2\">",
"        Balkan endemic nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etiology",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        Aristolochic acid",
"       </td>",
"       <td>",
"        Analgesics + addictive substances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progression to ESRD",
"       </td>",
"       <td>",
"        6 months to 2 years",
"       </td>",
"       <td>",
"        &gt;20 years",
"       </td>",
"       <td>",
"        &gt;10 to 15 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kidney imaging",
"       </td>",
"       <td>",
"        <p>",
"         Shrunken",
"        </p>",
"        <p>",
"         Irregular contours",
"        </p>",
"        <p>",
"         No calcifications",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Shrunken",
"        </p>",
"        <p>",
"         Smooth surface",
"        </p>",
"        <p>",
"         No calcifications",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Shrunken",
"        </p>",
"        <p>",
"         Irregular contours",
"        </p>",
"        <p>",
"         Papillary necrosis-calcifications",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Histology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cellular infiltration",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        +",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        +",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fibrosis",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrophy",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        +++",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capillarosclerosis",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apoptosis",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"       <td class=\"centered\">",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urothelial malignancies",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         +",
"        </p>",
"        <p>",
"         Upper tract",
"        </p>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         +",
"        </p>",
"        <p>",
"         Upper tract",
"        </p>",
"       </td>",
"       <td class=\"centered\">",
"        + (*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial occurrence",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ESRD: end-stage renal disease.",
"     <br/>",
"     * As long as phenacetin was part of the analgesic mixtures.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted by permission from: Macmillan Publishers Ltd: De Broe ME. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int 2012; 81:513. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_1005=[""].join("\n");
var outline_f0_62_1005=null;
var title_f0_62_1006="Epidemiology of unintended pregnancy";
var content_f0_62_1006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiology of unintended pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristics",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of pregnancies that are unintended, 2006",
"       </td>",
"       <td class=\"subtitle1\">",
"        Unintended pregnancy rate*, 2006",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         All women",
"        </strong>",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Age (years)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;15",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-19",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        15-17",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        18-19",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        103",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20-24",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        107",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25-29",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        30-34",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        35-39",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        &ge;40",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Educational attainment",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not HS graduate",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HS graduate/equivalent",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Some college/associate degree",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        49",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        College graduate",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Race and ethnicity",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White non-Hispanic",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Black non-Hispanic",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        91",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Hispanic",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Income as a percentage of poverty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;100 percent",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        132",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100-199 percent",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        &ge;200 percent",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Relationship status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Currently married",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Never married and not cohabiting",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Formerly married and not cohabiting",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Cohabiting",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        152",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Parity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No previous births",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        88",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        &ge;2",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Religious affiliation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protestant",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mainstream",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Evangelical",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Catholic",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        None",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: Numbers may not sum to group totals due to rounding.",
"    <div class=\"footnotes\">",
"     HS: high school.",
"     <br/>",
"     * Rates are per 1000 women aged 15-44 years.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The population denominator for the rates for women aged &lt;15 years is women aged 10-14 years; the denominator for the rates for women aged &ge;40 years is women aged 40-44 years.",
"     <br/>",
"     &Delta; Among women aged &ge;20 years.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Excludes women who self-identify as other non-Hispanic race/ethnic groups.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_1006=[""].join("\n");
var outline_f0_62_1006=null;
var title_f0_62_1007="Postinfarction angina with EKG changes predicts reinfarction";
var content_f0_62_1007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postinfarction angina with ST segment changes predicts reinfarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 366px; background-image: url(data:image/gif;base64,R0lGODlhwgFuAeYAAP///4CAgAAAAAAA7rOAzICzmUBAQMDAwJkAzP+AgAB3AMyA5oCA97NA2ebA8sDA+4C7gEBA8nBwcBAQEFBQUKCgoECZQDAwMCAgIP8AAPDw8LCwsNDQ0MDdwODg4JCQkGBgYP/AwP9AQJ8Qz79g3yAg8LlQ3MZw4tnA5tmg7Kww1oxAs/Pg+aYg0hAQ77Cw+t+w7/nw/OzQ9qCg+XBw9f+goNDQ/GBg9BCAEKDMoJDEkMDZzf8gIDAw8VBQ89OQ6UCMZlCiUDCRMODg/WCqYHCzcP+wsCCIIPD38PDw/tDm0JCQ+P9QULDVsP9gYP/w8P+QkP8QEP/g4ODu4GYAmf9wcKDGs/8wMABmM/D281CWc3kgpv/Q0BBwQCB5Tcag2bDQwDCDWWCggNDj2XAQn7yQ0+PQ7JZQueDs5jMAw6Bgv5C8pnCpjVB8ouzg85mZs1lzgGCGrgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADCAW4BAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v+bDgQYSLCgwYMIEypcyLChw4cQI0qcSLGixYsYM0Y8AO8Ah0EaKgSooGHQhgAfPAwKYECjy5cwY8qcSbOmTYot3XEIIMDAoAs9BVwQJEHohAkqAQwEyDTX0nYGBPQUtEEABQAUBGzQIGACgA8CJAh62rTsLLLsDkxVKiAA2wBq/33GHevWrF1YaNfNfft27t68dwOjApxuL1ixRT9wEAqg6lWlcEceOFBSsGVRhM9xAHuBsgcBGA5gEKBy9IasFegOGEDBQFSprikMrDD5su1Kmc29lsqxwmgMqQFwADpBrOoBhTRMFsnSwGjQrgceSHq7uqHc+wauhrQ8AIjXBkDApW79MnZ9A0sMiANmR5ZCIRLIT2AEkQeB32GL3zC9vN3z+QwUwQBtABEGFliEAQQbO8Q3XxRMPMHIfQO5NkFX0UlG2SL3nUSSf+kAiI+AAzwwSBY7gAFEAYU8wUQU9UnS4UCt7RZbhQZcOEF0F0wAwkcgliPiPSSaWMgaWhxSQ/8GNXCi3AHM8UeeIByAMMEFBPE32WRTBlnNkPaQOIMhOwCByJJVzKfmfCGEEhJBrsWZo1R07ihnSxJ9sGVlXtICZj0DMTAAA2SaiYgRa67JBBOy3LflASdJ9J1rdcYpwUO0bdjnJn8ykxMAEjwGSqCDGjJGF5RwEYU0jgr0UI103miRnnyW12kyHgSAAZ4X+BQKqYQagkUlUXCRzpPMVZTfrgFsAKRttyKjFp1S1TVqAIIGW8iwlCwqX5NNcXCScz2Jl5GWj27ZJTjRHqPcBSBM9uy1MwwQwSFdjEGJgwnwwEMC4Jal3Aca3XnnhdRSa6fBGTaEbroQqxtLu/AM9ID/vYcAsUMmNfTLQ4ybctIqxJE2xPDJcSKc8MoKo4yyQhzRxU0FKvt67cX3GqIxJ1BkAHLI1owcMckwr2RtNhdailkAOB+ixRqdpAn0iEdjU5wpFg9QwiEFAGHFDhtnkoAIagY89TsUHyMBCFi7tZ0hb8ABBBBeIOjF3AWEHQm/8vlr9tnrpG3MbmtdC8BqPURwAwNLPPAAAQQUArYVK2pSg78JtAm4OoIXI4Gcxhm+2uikp5EG6aizuEkNTvCwOedV/0OW40swcEMEPZiOOumqc8KDE9++LmTs1gwngGgfLK0I5Ies1vsm/GJOn/DsEl9NjxMc8LnyiXxxRvMDPP9J/8dVZAAF9d50ToxWBghk8yfYobAC+OKHYoS/P6N/jfrDTPCBARvAANt+ZT1ByI9+qOhZmoKnP2rwTxg8oVPMDJeIAxrCealA1Hwwl78GMuOBwvgfBTYwivjN74IDWFEBVshCFuotFDUo3988qAwQAiMAV/EAALmHCAsWwnktDGLlSoGmEEiBhsuw4S8mEJzv8PAQPiTE2xCholMYwQkiyEAGRAA8IyKRGEr0xfHG8j5PmBB8iijTKqQQHyxqkYsAC4HmvqiLMPbiAhfYwAauRkBFRHEQUzwEGlAFCzbKRwQi4IEWeYDINdVAQnR0hR15URWpIOWJhnADGdCoCG7hQv+OHVMTEzLAhA5Gsm3dyFVKSlhAQVCBk4noAhqE8YQaQOgJRpjhKfu4DQmEjpWLeCUKF7GzYbgoChmQHsB2yUttOLEU5xHmDwfggghEwAcMYJzjbAAAIIDBGEaoTyg9lrkjMpNTrZTGByZAkOBQMBHSlOLu5rkiKzCDdVncYhfNec5JTHIXhCtjJ6KZCBvQLps+sKYLgOgFLxTAnswwpBv1maiKQsFY/YQMNzjwqHmZMZ3xdMQQpmiFAjT0m9AwZEUT9SIIMTCS/9SFBj7HgRFi0hAhbUTTjoQFlIKDC1Do27/oI8cQYBR9Mc1FVo4HAlHBD6SS2Gkh2KDCILqQG6H/RCQiFanFDFxBq0yYDxSKCqKk4kIA/3PfTQuxBTNEQqqE2IFVW6gFMaCjqCEYJxZFcIWufhWOYsVrUSGZnXRGg30HMIBTP7qIFaAgEoK6gSR2EIZ7FDWo89mrVhHZ1c5GYbNaXeBKR+tFbJj1FlaawGjc+dTGPhYS2ZqEJ23DRsHybbSJmihgxXrUDxoWGhrICh+biQjHQrZUkgjDCyOpUlFGAUKmLMZpn/EmEgriTR+SmSKMC4kbIDcSYtBCe2aZUUJwIQFMSuJvn2G84UJCA0ABinGAEpWhaDcR3H3EgIwUCbnOrQtY6ALelrtLNOFWTaXFxXRrMRoDAGW9hDgM/wBG4wHHYEUrZETIBPPriP1mAg0pEoMXygsADR44AboFXtkI24oF0wLDWBEoI3gilqgIpC18UQqeDLLh1+q3RJ3wAkRJ/IjmzmeUTNDlKVx8luB4R0awudCN3cKTupyHw41YzRA6YYURExkTtVTmicc85jkyWRaEg00kduIbAXwlLKBC630RoYYyRGI1JbAmDbK5TUs49D1fxsQ4yUxo0hqNG5+70y8bQZusiOUzoaHwnA/BPEjMc3eU2IEWsKAFKwA60ME4szKkggFrtRk4h15e5CRh0AdkkwbWVA9yKpEFK2y6058GNS9Ebdp0VloTgaS1rTk91xYSWNer4PX+fP+9Asg5+9k+fkSwL1HrYq9wiMiWJIQBlU4UPPvbzZbEtEWxwmy/QtmxqNU7JfFrac/aFOU2d4u3/QzRBEDdnKBYux0x7lDEW97JprczdNgV6zKWEvvO8rtL8W+ApwLds6hNaxG+aksvnBQNd/iSBa6MmiqNuJFIOCP6DYquWdvax9Y4JCDOiueoGeSQEPkiSP4JuZ58rthWuT85ngyroJLi4r64LWytc9zwHBkUWDTMHyFzRVyadLHIAhZyXfRHsHwVVvr4ukNecXc/Xeis0EIBqF71GR/9GAFdqyOaPgmao4KyXRCDvsreiKtLQ99dx4TbUzEGMXQhDJ6muyLsror/naxS7Y1ge9BtUeswxH3ugi8E4VFRgTp5dKBHV/ydwS6Lvv/95qAvdsr1N/lTTIACkLrAYjFfCc1bfBfVDr3sr10/D5beFGPUMeIZ4Xp3byPjNLx9KS5Qagm49+CT6D2/OT8N4Nv+7MbgAMIugO98Zz7vl9j7M5zfQOGbwiOkwDsntO8Mk8/+/HMdPZGgP4wAeCBZI9n9Igiwgi+gINqVIH8zbI7+/tMeIN4XCseTdkvnCN62AiuwBVRABVuAgASAfwpXFtxHNdpAGRy1JZdnfZxwf18QbpsngbUXIOxHDBIQHAQjf5RQBt+zeV/HfO8wgeunDe8SLwfQGig4CX+k/3AtiA8wGCYjGAzTQi0DtHWakIOWcDFbcw89yG3akCvMghLVh06fYAabtAlwRQ9LSA8BKAobkBrKEYWaYEc5ZQn1kjP2kIXzsIWhoHoAoAECdIOTMIaVEFtKWFX+53/q51vckHssAYeSQAZupQl0aA/8d4f9l3N394PC4D+CQAGrp4GfgGWWMCBj0kBoiAxqCAogIBRAwVrI1wmSWAkeZokh6AyZ+AkasInH94mccAZ2pgnq0TiuxgCwFgGylgRAc4nHcIqewAEZOHGeQH/fBm0s+HVTo4vGwIud4Bo/5wneNoyQ44HulmcRsGcMQDsD0APHWIrNoIycsAH2FX6KyP902FcJL4AxuciNergNBEiEpKB8jCAoNLCN1uCNm5BorqF0kIgK8LgINPBdm4KM0jWO6MBk/agIA/IC9PglBPkLHpePfrgJB5kIPQBk6ViPDekLQBErk/AmH1AZ2MUnBlmOlNCC+vcP5od+eXgL9qgJAlB5ACAekgBfQTEBJUFfjDFppTCRiGCSLmgWhTh7iNgLLZkJxxMa2xMJajEUNmZhWWFdI2kKJxkkAokXGdkLpbaJPhcJNEl8bFNlOcYSGiYKPLl4pAhBV6kLFsgBwUUBYJgIqahaQqEBYAmWOjaWoVCWxXhpC3lDaZkLx1OClgAWbpEVKAFniaGT70iSnmD/kn35C0VpCVbxhPEXCZXXGZ0IaaJBGoo5CnoJbD9ZHVV5bn+JC0WRMDLGCMYHGnVxau4Ula8wlYExmtq2DcNBg+BXgGTJmKfgmKKpjixZmuEAm67gm7dBm/M2MzUTkZrwmaNgnEyBnKwQmZeQNBCpm3nJm7AAnQAhnQHHDavojp6pnbmwGo4zA9kUa7KJDt6pCtRpCWvTjKfgnKzAnfXQng8nnLjQjsA4n+SJC3hmTdk0A46znueAn4Ohn7eAjwagj1KYCvRZC+b5AOjJAOoZmuSQkoa4obP3Qu9JlApKCMIIjRD4C/apDkHJoSp6ch4aomfxfgXhiayXCs84jNIo/wwBGgEDWqAYClMuKgsDSC2pGYY/qggq+Aw5ao19xkwfKgkW2FHMKQpGiAw+uUtN2pE0ZVPYSaMn9Ayt9moXaqVFKgtLdQBNFaWhQIXacKJTc6WSgFbt04dbmgpyKA1sCjRuGgmIpVhoGgp1ug05uqNG8qW0GKaWkaeQkFqr1aegAIjj4JPGeKhjmm7C5aAPKguh6A3nmZ62mKR89gA2sBqEWouyppD9gKiP4IvyCQuZCg8m6QKyM6mwwIzQJKuH4Ir44KnX+AADIln+gKqOAI6r+gr0Z38lig8LVQIM8AJbVljcwJ+s+AoHmIAL2IDNdqzvYAMLRTrVtKzNyoS9BP86jGoKHHij9TAEL2Ch20o61KikoNoOwFoLpxih5ICu6gqpl8ZN3xCvfmKrMfef9zCqF/p0sFo9ZjGvACsYSzAAPjCc/sqQvkCv++ADA3ADjgOmnVqwELtRGDiu/JiwgbGuT2eqDvSwrLBULyeetiCx+RCqWqNnn2oD3uWrJbuHWDIbHuufDXSOq2FN15RNDECgjoOLmGiyq9Cgw4oLLGsXIuuTPotNgvoARKtgRqsKB7AwlpoJCItESeA4FAq0CWVN+Pp1JVCJybkNKlM4/akLS7spXbupCOWzPtkDU5uf4Jm1+7gLbctMMyBrYwupVle1qfA5HTunsrC355QEFfn/t3d6HYKLCtA6o7wwoiQaeePXoxq1DfAno3mrCzVqoyBruTOHufx6Fo+bfKEruomgf6W7CCJkcCr7C4hbdKx7uqZwmlIBu9EqDLOrc6tRTQKaTS/gON+audqAY8E1pHCZLiURkqlmDL2rcvjamdQAY0nJHQnDETgZjh9arPenupgwBI6TrpwaAdtKvdOQFQ4mZ1y5HFJRYT73lOjrC9OqgAzogNgKvpbQunBZqZawiV+JY3YplgcxQcRQrqmrv2Y3M5wbCZ/BmXWJY3dZwMoQvYLHv4hgg5cAwIIgYYlpvM9gwXSHwYfgG4WrlO8rCJopaSDsDCJcdiRsCJHbCFHx/0uu+bwhnMAKPHi2Wwqbm7Nsq8M7jAgxPAjHQxtJuwwvXHVFLAhtAS8nvLbNsMRF18QAkGZqu7tKLMRD7Lgy+AGU2cBEKg1UrHNWTCXrIsXMUMYqd8Z2Gw1srHFunKBk3GzQeMd47Gz5y8Q9vI7Q8Ll5HMjOpgZboMBzfIG5GbvmsAVfoL9ujLJZLLnt8AWFDL5uLBTtBMTYsAVqgMd7HGhujLS1Gg+A/GzmKm9ufLVap8b0EMdl1cejkLbKiwlzHIxc7KN3m8Tz4Mr+4caEKy+aHA68bCuwLAozfKn4QLnD+Mm4rLkxGszgUMrOdsoZVcu6zA/DfLDFLAqvC0xmkf/NZeHL1KK7kswU4NwUl+wWyQvN6XDOTHHJ1nW9rNwPyizI9nzP+JzP+rzP/NzP/rzMOIwN6gsUyWO4+CDN/5zQCr3QDN3Q/+xjbhxcXYG3tLzNXSwL1jzKF80OVswwFL2/Fr3RpHm8KzPLl5DRIr0IbhwagiCTBp3S3HDJBS3PWgzTDvusPQEUQzjPNr2vIe0JEm0Vb1nRPX0Oc/yFmqLIRb0Nblx5x3MBH210Sz083IABxKdWLz3VG3u8iaU9Jg3SWj0OKw0CWBKeyBzW6fPTnVBJXZHGY4zWBrtRKOHWbw3Xad0NJ5Erv1jXdh3Tas0Jp1mDO13Tfb3VSEPWWK3/1IUdDZfc1c80k8xxXSKRXS282Mv2rMSXFQW9ZkmDAYKwvQFt2Ri5UdM31IgwGs/ilDCG0mhdy4m8ZqAxGlcRwVb216KttbatCbRKCUt5AJ1I2/N726aY21r71YmwGD5RZR7MvgR8E8793NAd3dI93dRdEJ+iDUWxyo9gGkAxHaCxmUnhKg1T3c1B3gYx3uSN3uZd3uvN3u2t3tKB0xwpCe0VHDcsef7KchBnd/ttsqxdmwA+0gI+MQ+r38QNP27mS3Qc4Aw+nVXb3wQu1m622xp9tgNu4VaZ4Ro+nBNu3Hz9nRuO4Rfu4BEuDjyRI3YS1Sed3/5d4A/u4iXO4ahZ/+EkHuI1HuMifuPgIDSvHQoS1wo/7gpBzgpDLuQGTORHjuTCveRM3uR24byrkC5E/ixQ/n3PIuWp4AEE85GSPRKmrQlaDoWCgOWlsBle3uWUfRegvQoJU3gn/hNBEY6jsBOF0+apsBv2teakgOdOTC2nIKSfHeeCodrkXAq8UeR7/nKEXgrgYcTHg+ijsBVueDyLTgqSPhoccehJHgqp8cCNEb8w9h8CLMGpABuoF+VrAdylsBcAYOqbbgoUpuqwzpmujgraM+pURuoHi+urIBuqSNeg8Be8vuqF4+ttvQoSJuukIGFY4R3HbgoVUMN8YZd2sdybfbS5Z+trYe3fF//JNqYKRTFA3F4K4S7D2W4KNjbudrHCnJkKvu3sNpkKmyEUnvHdLDznnEEZ766KX84JWVFq42Hv7T4K/y4d+94V/X4J736aHsDuwN4P953lG3kBex0KhNMbvyHGy0gt0zHxFQ8KCeMWET8KIe8BHm8KJk9q1jXyTt7yLv/yMB/zMj/zNF/zNn/zOJ/zOr/zPN/zPi9vj7IJG+AaH0/uHj4IHGAAGo8I0V70Py9GdbL0jfAZWPLwiS4jcOEIUTHm7vf0PedmKd8bsUFCeQ0AIqEBMxUdhLCJSp8rkJIaVdKglTESLFEBNeWWhOD2XegBkyIBJSESp0EBQDL0FDAaVNH/GgUtEIFPl0oPAG4PGQQBADXoGsmzmXAhECqR9j/i+M3yOQd+81IhCJV3FUmnK6RRecmjWhPGThLg2XCOARKgFknjAVcSAFfS5z0CGjpNCLLfE4nl7GwTFVYNGp+OJYbvGEUhFjxxJV2R+/eBY65BHEohHlFRATTTEyIxRj0SAD3y/D1xIVLv9a4Q+pI/FblCLpRxJVWR+j7S9YOgFm6hFsYBFiRUFB8xFTyR6e8j/4MACBUgBgIGAIQAABcCABQCHoeMjhqKEwABAgcAhZeZBwIBiZUcABofFIuhiJ0HHAISABsCH5+hsqGiubq7vL2+v8DBwsPExcbHyMnKy8zN/8ACjAAVAiAeExeCmQAgAouUHBQYAhOQibUA56zqnJianKLpEq+fhquI9oz464bt6dyklT58ABUpUT+Ctc6lc8awocOHECNKnEgxGLQDFSaQ+0ThACFNnwRQSGSggkcBANEhJAjAVUcMljbx0/bOHEtCG6bVi4YIU4AN4gAM/ClyH6tz3EAccIfhgDxVAjZwaAdgQlNHHBSyrMi1q9evYMOGhQaNAkBu17QBELchkSMBGCrk0opLmrgLANnRNASPJYcJhTjp00AIQ1AAEgBToERV71KCZKFJg0bIFuAPVDksiqsy1EKxoEOLHk269C4NcE2rXs26tevXsBsOjU27tv/t27hz697Nu7fv38CDCx9OvLjx48iTK1/OvLnz59CjS59Ovbr169iza9/Ovbv37+DDix9Pvrz58+jTq1/Pvr3798WWUtJwoByxCgZSjgdXsjaH/sEYAIsyEvAFH3VldWbMAQHYx9tnEsEUgCar1ZSIBxMKY+ExFdR1oHRkPYbLBwZQ0JYuJAroAYOQgENBAA1iuEGBuHAwCAVy5UKiiYl06MEHDqYowY+4BPCBND8JqMEgpDB4AAVmbVPIiCWe2OEGSjKZiJAOalAgCKRMg4GHDHJgEjoUKFlKikcGkKObl1QwVZxzahBAlQDISONkY9qHoSZeGmBAKKYIemQhJIL/MN+dPMZ5p5xQUtJhIgUaAOaHsTEI46acdpohL91YdQtirzhyYiLcSBDABQxmYs0Ed3pCGWAVeNBNACCMJIo8EpgaCWAUSqkqq/+4AkIkho1TWCeDaqQIXIbw6mth4kywbKqrBlvJquTIY20umABGFAXyjESIBInJlAgn40jWLiMXwLpIVrMKUIG3+fUVioQSYBAJupZAc4E4x8a7KkqbhArXIseuMmZi/mL6mqaeVvzpLoXoRNA1pRQliiMvatIOJnIdZAsormAgwQeUiMIxauYK0PLHImX4CboII3JOT9rII2IiLxelM0GIgHxxS6/EMou64EblFigBiGPshUyz/3uBKN0k4sqg3ExI0KgbnqMRCA1Onae6qOU3ZdfqNraTOQUCJvFygkETyjsWLrlIVCNrY7KCWAJ2NdZ81X0aCHu3BRMGgw8NlTp/V/32zozoDc2pdDEtClWRcPoZ3obU9A49m/58TtgEgVPtNB6CTjqM7swUe0GymLjI3MpxElIopmJypCgg0CIPZpnUfpLpoBwAwgYHOEvzBr4XpEvwTi2NydIFUd7JBxs4y1FbvS/teEHUD5+LVU8ivCHnA3W0wbEabbDB1YBJwE3oBtakkUkfmLTS3U2xz85MQoi/TEB+VwNdVSbAP7k4Rl08+8lhcHecd7BNA46YwIA2BxgNqv/DW4tAXoP2hpdcYHAcA1oFuDo4IFvJjCSM0B4mxIEBgBDCEif0YPaIxogAsFAXmoFLjtanlkuIoyjgoIw0NCIP/BFOFEmEC/P+1wmE2YR30OBMFJ2orihioC0PNJwGNjNBCoaHFvN7oVdkcaxgcM6McIyjKI54gVN1xRHa8sUb5cjHPvrxj4AMpCAHSchCGvKQiExke54QghAYgwsiqIFEqiACRVpSPFXIQAaMUAwpJMCRERFBBi5JSu/wQJNOSEQIEmAEJ4iAkwDgAhOYkIAESMGTjkxADaAgAic8AQAhYIIIRACFXfCSCbCsAStnyQUAiBIARrAlAJT5y1JaEzr/RsgAFKKQgV8mIANREGUGbhmFKCRAlI3MQAIAoMkrnDKVCXDCOTMgSVFksgpM2KQzM8CDK/Bzn9PUJgCiwINrGpQ2q6ylQhfK0FqCUhdOGGdEJflNR2ZylfQEQEVDoE52VvIJGfgoFJjgz3WKIgpXAABImQBQAPgToE9AaTaLedCatiahDc2pQ3cB0pCeMqUV1WgGMJrLoXJ0nSFNRFKvEAUoQKGjokiqR1v6zGcCIKL+rKZNtzqcp8ozAafkQlArmk0mhACdR53qVPkZgkyaNBH5jKZArVrVUQJTkyzlql6Dk9VE3HOsQwVAJlFq1I5KNak10KQo36rSfEahComg/+sorQqAU8Jyr5hlDhRCYIS+egWkBc2saJVzygxc4bJdeSpjR8va1rr2tbCNrWxnS9va2va2uM2tbnfL2976VjxJeMADjGGDCMygIsU9bi6SMAMGMMAGABCudB8whNvMIALQ/S3uaDCAAbygGENgwHAp8oABMCAXNnCBCyJQggGUt7vwPS9pBhABYDDAvdrFXXsHcINEPIABL7hBBL4LABv4wAfOHUJ4h8uAGSwhAjdIQnR9EIEILEEXD6CwhRPR4AdHGABJELAPzJuLCHg3ES+wgXB7MIAlUDcXL6DwDYY7BAHfILsvgLBzARDeAGM3xzRIRBIYEAEffPe/Pv7uDP8GUAIGVFcUQ6BBkV9w3yUImMBShjB0kXxlFOtYvhmOAA0knIQsyze/tPmvc9fM5jaLlxcvaLELBiDh+663uwpWL5HdW97zdrcH7e0vA26wZ+VymNAmPu6fAw0AFtPgBiQWBaRd4IMlPBkAJh6vKJaMYAQPwQU9YIB6ARDnULc3ut01sQtK0N7j9sAFDGCxDexs4gFEeQDrzS6I9SxgWuMZAE2mwaoB4Gtbl5oBp46zD7jrA2DDmgYlQHNt1Ozmar95F5Cu8QCOe9/hcve/2yY2n0lMXxCXOwlL8AGLzwzidK8bAOemrw34i2p2hxi+LshupnWxhAGE+rj9RrR7TVz/XRPXG9MDqPe8IzBo83YbAN+Gd31z0W/lhhe/EX+AlOcsbm8P3NYIB8CInXtq9RL60tJOThJS3d4edLzjD+92nyWeiHK/egn9ZvfNc05zic985qKQcHRNLN9962LPA6DBfQmdYIOHfOYG73N5Ge5ccDMYv+XOxcM5jN9uK/sFLH55t51ucKKvucA+aK8LUJ5y4wSc5AOYddfdq+wHZHrmWS83kzUe6ZqXgO9+njh9k7BqwJf4Bi94AIvHa3RRLIEGD+D0vHuQeBrYgLsAPjXUEz5z9c7gAUto7tyHu/dLTz7yCB79fTOf8Ji7F/MvOHW/ffCAAGP68ybWdduNw2Kh/3NX6aOHOK4Xj3fB13fJ9O07AJBP9J6XewZzbr7jWexvAiNc0yjerw8kDPY/DyEJJmY150kcdRIbuLsloHLw7xt3GFPfuaNPAovFL3b3gp/Jpya29kWOfkPv3jou1n1CNxxD8HnQ53K1UYCRB2r/Vx77RXnGkV7d5QO6BxsSOAAU2IAauIEc2IEe+IEgGIIiOIIkWIImeIIomIKqgQQd0AHGoAQWkAMVAYMyKAo5YAFKIBE3mIMQsYPGYAFFEBZFYAEA4IO5YIQq+BBFoAAK0ATFMAUQ4IIU0QEKAAG5AAEKIIUQgYVa6BAdAAFTYAwKQIRgYQEKAABfGIZmmAhpmP+EEHEETEgEbAgBTUAEFuCEAKAEQRAEEACGUOiCEJADOmABRIAEaBgEFmABOqALHYCIipgIgTiIhQgASGCHQVCFV6gAOmCHeNiIQGiIX9gEe4gEEBCDiaAEdlgEhpiHjpiFTQCGRQgBSJADdLiHOeiJjxiLTfCJdniLsIgEg5iLbOiIiwgAY1iKVggAkUiIhogEQ0gEPBiISmCFtLiLqtiLADAFdviJALCGadgBcBiFbUiKFhAEeCiKhNiFHviFfdiO7viOUcgLTaCJOKAAhoiFOGCGCjAFU4ADOFCKWUiFVsiEQgCHcggBRACQNQiJCWmGMkiQBgkAQqAARUAEmCj/Cvioj1Mwj0GwhEGgjAqAAxMpkvXIjyIJASKZjf4IkB2QA5oIADhwBN2oAEcwkTKJkAo5k0cAh/lIkyDpgmZYBEWAA1fYkArwkDhQBJe4iBCpAHIoBP8IlWEYkkyokzxphjLZARaAkE45kz+ZA/UYg1wokVGpAErgknzIhyLIjvDYlvG4CxapjUf5kwCwhF84l1wokMZIhEgwhpSoA0EwkcmYCMAYmJjol32Jg12plxiZhXWZhZfYh3BIl37JhTrQhI+pBJcpg1yIBCI5j4u4hhJ5hoUpmF6pl2vIhUrQldmYC6V5mHzpl4g5hqsZhKBpjEIgCt6IiaKZA3bol6np/5iiqZrHaJEQcJlCEIhuSAx9OYZwmJtjyYXRGZCwmQh+CZU6cJmDSZbZWZ17qZeMCYmOyYVm6I6USYTSOZ5ZOJ0uaJETaYiiuYbYqZ2nyZtnmJcXqQvz6Z2ySYZjCJ7eWZ9WuIZLWARUSITBCZRn+JMH2o6AqI9BuJzBcJkJCQFwOI3q2QEcqZXUOZD+SYQ02QFLuJ0hOqJ7aZ0W4JlHIKL5SZeWqQBBoKEH6ZiVmYWrGaNHQJRUGKNm6IJUCKOJEJ9nWKL2iYZFOpb+2ARNkJuiQKQDKQQdYJFM+aEwuaKXmIN+GaRniJpnaIZN4JIIep/C2YQY6oL+mAMdoAOCaP+gaCmhwfCeiVCg7PmYItmhJ3qiLjmGLZqn5XmnfgmWerqdc2qhTPiRY1mjLpgDz8mDS1inUgiHeCikRciEfbqbAyqmLqiHlHqElHqY9UiRKBqqSmCTNZilAuqVShCWwImpANAE9agDY6mpNKmkcAijq+imzqADGgqnzdGXMomriFSrQoCHzUGfwHqsyJqsyrqszNqszvqs0Bqt0jqt1CpaMeAADmAMMtAAKcAMMrAAC5ACMcAC2Fqu2XobDXACuZGuubCt3RoR7gqv3GoMJ9AAYZECDSAD8dqu86oeJ4AACAADxcACC3CuyUACCKACDYAADbAAAPuwCFAaDmuwvcD/sLlhsaLgAAiwABKhsRwLEQRLscKwsGExsSELABMLACcbHQ4Ari77sjD7siLbAgBLAonQsjBAAg0gsAAgAyZgAuDKAicbrj/QACQQAwDgACbQAA3wA72gsSqQCDHwA+T6AwmLrbkQA/XasImAr02bCD4LtAvAAiibAgvArWGLtADgtU5btkV7tCywsCTwrlJbtF/LsG+LtF5rAgJLsDBQrx8bAzoLrtkaA2fLt4lgtydAtrvAAjqbrnq7ADDwszKQCGeLsPaasQhwAoCbCI5rtJXrtzorAzDArgCgtaArtTprAhv7rdnasjKAszrbt497AkiLsz9ruPO6simwtLYr/wqfC7kAsLCle7RrK7mUm7gNgLjHywJUi7smoLvvurUkULkmW7BxiwBzy7tM27YysLp0KxwtG7PkK7O5AAMI8AMjgABI67AjsLAIILQjMAJniwDYurEAALAqQLM2uwAkUL/hC7z6ewI8m7QYmwstQL8n0AIA8K8nwLpUO7/1m636u74toALa28CbC8H5m7D8KwM0qwLqKgoLy7kj0MH7m8EmcAILQLPkCrANsL7disEngLAcqwL0i8Hfu7kLoAIie7MNi7A2u7AXjAAM/K9Ae8AGzLAyzAIjoAILML9LvLAj0AI0O8M5PAJkS8M2zAIIYAIAwLoEiwDvC7DkGsQZ7P++GPzE6/vCHOuwQNsCBusAaDzE2ovEw2vEGHzEGxyweby+LUvGa4zD8QsALbAAJ1DFKGu/HgvCCXsCHqvBD5y+XgzFJADG3IGwjosA3Zqy/xrInczI+GuxMUDKP2ACGPyxuwADNFuzN6vEiTC//0u2VQyuDOuwoUzB9pqyFlvLDmuvpGyxKSsKMpDBKpu/9lrK9kqwDUCz98ux6FuwGdzIt2zDrAu0PywKKaCzFkuyAIDBAKDIyJwLkRzNVvu/C/vMeWzAC1DM6oq+P1DMNhvJC+vFYOzJ9ru23LzL+SzMosyx4hwDatu1+7zO3xyx3gzOT3y6X5zHasvL/Py69br/vouszikbyb7MsMXcAifwAwOdHaXMsCFc0RWdshMbyRhrsTj8A1arylnruSkAsK+cue1qAjSrxUbssmabzxBN0hab0+DarSkd0eSMv6Iw1E6sAtv8z+wcyR6rsQ1LuIKLwX68Cw4M1QZNskNd1BzrsQ77v0FLzxH71PhL1l2NvzGNwQJr0vZ71f6syxWN0jSdC25tr95MsncdsVvtzT4d0ejLt+B80vh70aN8yEENAKW7vlG7HecMrjT7rTxtv39Nx0y91UbsAP8K0HPtAC3wAw5gtZmL1brArZTtsxvrAGY72ek8zj3NugVrtuPM2qedC/MLAzAQtUOtsSZA2ers/7GlLMeZHc4jkAKfvc2e/a/xbNSJQLwxbdcRu87MrcRO3boJCwOYHbv4S7IYLcesKwMxUMWYjb/fTcaWG9mUDQPN3ddxjb8QrLQGG93O/dkNnddhHLAO67R83dMT67CSS7Pr/canHcmujdoFSwLWLcXbgcFq68Bsna3/+sSVnbkWG9MMS93hywImsL4jYLwGPNeJwLpG3K2Cq+Ec++AYDNc9PeJkzLFbzQI0i8lgC+LALOH2irAQ3ttovb4Ly7GmbcQwEMVkrK5Wy7hgq+Pd/Nwk68gLu9lljb+3rb9uvM6RLAN7/K4pYOQfi7Aj3OAyYORE/daRrOItQORdXuHOrZHjSEvfMcC6IzDC+d3PER0De+zfgs2xLv7FYU4CJM4CVK0Clbsenv3kHy0MP8DAFRHoCm4bxK20VQ0MJmCzvoHBRC6trawCBUwMkssVlX7psYGwOT0MJjDpulHMHl6tpn7qqJ7qqr7qrN7qrv7qsB7rsj7rtF7rtn7ruJ7rur7rvN7rvv7rwB7swj7sxF7s4xEIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 40,848 patients with an acute myocardial infarction entered into GUSTO-I, 20 percent had recurrent ischemia after thrombolytic therapy. The 30-day reinfarction rate was significantly higher in patients with recurrent ischemia associated with ST segment changes compared to those without recurrent ischemia or those with recurrent ischemia without ST segment changes (p &lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Betriu A, Califf RM, Bosch X, et al, for the GUSTO-I Investigators. J Am Coll Cardiol 1998; 31:94.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_1007=[""].join("\n");
var outline_f0_62_1007=null;
var title_f0_62_992="Thyroid nodule with halo Echo";
var content_f0_62_992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thyroid nodule with halo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel: A sonogram of the left lobe of the thyroid gland that shows a hypoechoic nodule that is surrounded by a \"halo.\" Lower panel: Doppler image shows that the \"halo\" is vascular.",
"    <div class=\"footnotes\">",
"     N: nodule; L: thyroid lobe.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manfred Blum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_992=[""].join("\n");
var outline_f0_62_992=null;
var title_f0_62_993="Appendix carcinoid ENDO";
var content_f0_62_993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic image of an appendiceal carcinoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient was a 42-year-old woman who underwent colonoscopy because of an episode of ischemic colitis of the descending colon to rule out underlying IBD or residual injury. There was no residual colitis, but the appendiceal orifice was characterized by a submucosal yellowish mass which was firm when pushed on with the closed biopsy forceps. Biopsies obtained with the forcep showed a carcinoid tumor. CT scan showed no lesions, although the appendix did not fill with contrast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D. Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_993=[""].join("\n");
var outline_f0_62_993=null;
var title_f0_62_994="Patient information: Disseminated intravascular coagulation (The Basics)";
var content_f0_62_994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/46/5859\">",
"         Patient information: Acute kidney failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/14/4322\">",
"         Patient information: Adult respiratory distress syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/59/23474\">",
"         Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/54/8034\">",
"         Patient information: Delirium (confusion) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33569\">",
"         Patient information: Sepsis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10066\">",
"         Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/57/11155\">",
"         Patient information: Delirium (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Disseminated intravascular coagulation (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/disseminated-intravascular-coagulation-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25859865\">",
"      <span class=\"h1\">",
"       What is disseminated intravascular coagulation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation, or &ldquo;DIC,&rdquo; is a serious condition that makes people bleed too easily, get blood clots too easily, or both.",
"     </p>",
"     <p>",
"      DIC is most likely to happen in people with certain conditions, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Sepsis &ndash; Sepsis is a serious illness that happens when an infection affects the whole body in a certain way.",
"       </li>",
"       <li>",
"        A recent severe injury or major surgery",
"       </li>",
"       <li>",
"        Cancer, especially cancer that has spread throughout a person&rsquo;s body",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      DIC can happen all of a sudden or slowly over time. When DIC happens suddenly, doctors call it &ldquo;acute DIC.&rdquo; When DIC happens slowly, doctors call it &ldquo;chronic DIC.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25859880\">",
"      <span class=\"h1\">",
"       What are the symptoms of DIC?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on what condition is causing the DIC and whether the DIC is acute or chronic.",
"     </p>",
"     <p>",
"      Common symptoms of acute DIC include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bleeding too easily &ndash; People can bleed from cuts in their skin. They can also bleed under the skin or inside the body. Bleeding under the skin can cause large bruises or a rash of red or purple spots that are not painful and do not go away when touched.",
"       </li>",
"       <li>",
"        Getting blood clots too easily &ndash; Blood clots can form in and damage different organs in the body. Depending on the organ involved, symptoms can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Urinating less than usual, or having red or brown urine",
"       </li>",
"       <li>",
"        Jaundice, which is when the skin or white part of the eye turns yellow",
"       </li>",
"       <li>",
"        Coughing up blood or having trouble breathing",
"       </li>",
"       <li>",
"        Confusion, trouble thinking clearly, or going into a coma",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with chronic DIC usually have no symptoms or only mild symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25859895\">",
"      <span class=\"h1\">",
"       Is there a test for DIC?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for DIC, the doctor will do different blood tests. These blood tests can also help the doctor tell whether a person&rsquo;s DIC is acute or chronic.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25859910\">",
"      <span class=\"h1\">",
"       How is DIC treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for DIC involves different steps.",
"     </p>",
"     <p>",
"      First, the doctor will treat the condition that led to the DIC.",
"     </p>",
"     <p>",
"      After that, treatment depends on a person&rsquo;s symptoms. People with no symptoms or mild symptoms might not need other treatment.",
"     </p>",
"     <p>",
"      People who are bleeding a lot, or who are likely to bleed because of recent surgery, are usually treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Platelets &ndash; Platelets are pieces of cells that help blood to clot.",
"       </li>",
"       <li>",
"        Clotting factors &ndash; Clotting factors are proteins that help keep people from bleeding or getting blood clots too easily.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with chronic DIC who get blood clots too easily might be treated with a medicine to prevent blood clots.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25859925\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       Patient information: Sepsis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=see_link\">",
"       Patient information: Adult respiratory distress syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/54/8034?source=see_link\">",
"       Patient information: Delirium (confusion) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       Patient information: Acute kidney failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=see_link\">",
"       Patient information: Delirium (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/62/994?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17113 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_994=[""].join("\n");
var outline_f0_62_994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25859865\">",
"      What is disseminated intravascular coagulation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25859880\">",
"      What are the symptoms of DIC?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25859895\">",
"      Is there a test for DIC?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25859910\">",
"      How is DIC treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25859925\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=related_link\">",
"      Patient information: Adult respiratory distress syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=related_link\">",
"      Patient information: Delirium (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/54/8034?source=related_link\">",
"      Patient information: Delirium (confusion) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_62_995="Anti GERD operations";
var content_f0_62_995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Three most commonly performed antireflux operations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nissen fundoplication shown at top. Most surgeons perform a \"floppy\" wrap over a 50 French Maloney dilator and add sutures posterioriorly to approximate the crura of the diaphragm. The Belsey Mark IV repair (lower left) is performed transthoracically, while the Hill procedure (lower right) is performed via the abdominal route.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kahrilas, PJ, Hogan, WJ. Gastroesophageal reflux disease. In: Gastrointestinal Disease: Pathophysiology, Diagnosis, Management, Sleisenger, MH, Fordtran, JS (Eds), WB Saunders, Philadelphia 1993. p. 396. Copyright &copy; 1993 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_995=[""].join("\n");
var outline_f0_62_995=null;
var title_f0_62_996="ECG tutorial: Pacemakers";
var content_f0_62_996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Pacemakers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/996/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/996/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/996/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/996/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/996/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/996/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/62/996/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H90656333\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial and ventricular pacing can be seen on the electrocardiogram (ECG) as a pacing stimulus (spike) followed by a P wave or QRS complex, respectively. The ECG has the ability to show normal and abnormal pacemaker function. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ATRIAL PACING ONLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial pacing appears on the ECG as a single pacemaker stimulus followed by a P wave (",
"    <a class=\"graphic graphic_waveform graphicRef82560 \" href=\"UTD.htm?34/31/35318\">",
"     waveform 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .) The morphology of the P wave depends upon the location of the atrial lead; it may be normal, diminutive, biphasic, or negative. The PR interval and configuration of the QRS complex are similar to those seen in sinus rhythm. They are independent of the atrial pacemaker; thus, the duration and configuration are determined by the intrinsic characteristics of the patient's conduction system.",
"   </p>",
"   <p>",
"    There is 100 percent capture if the rhythm is entirely paced. However, there may be intermittent capture when the atrial pacemaker is in a demand mode and is activated only when the intrinsic atrial rate falls below a preset level. In these cases, a paced beat will be seen after a pause that is equal to this lower predetermined heart rate. For example, if the pacemaker is set at 60",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    the pacemaker will only pace if the rate falls below 60",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    or there is a pause of one second (60",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    &divide; 60",
"    <span class=\"nowrap\">",
"     sec/min).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VENTRICULAR PACING ONLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular demand pacing appears on the electrocardiogram as a single pacemaker spike followed by a QRS complex that is wide, bizarre, and resembles a ventricular beat (",
"    <a class=\"graphic graphic_waveform graphicRef66752 \" href=\"UTD.htm?13/8/13447\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .) The pacemaker lead is usually in the right ventricular apex; thus, the paced QRS complex has a left bundle branch block (LBBB) configuration since right ventricular activation occurs before activation of the left ventricle, and is negative in the inferior leads. Sometimes, the lead may be placed higher up in the right ventricular septum or outflow tract, and while there is still a LBBB pattern, the inferior leads may have variable axis. There may or may not be atrial activity noted, depending upon the nature of the patient's underlying rhythm, the atrial rate, and the occurrence of ventriculoatrial conduction via the atrioventricular (AV) node. If intrinsic or native atrial activity is present with a single chamber ventricular-only pacemaker, it occurs at a rate that differs from the ventricular rate since it is dissociated from the QRS complex. Frequently, ventricular demand pacing is seen in association with atrial fibrillation.",
"   </p>",
"   <p>",
"    There may be episodic pacing in patients who have a ventricular demand pacemaker. The pacemaker is activated and delivers a stimulus only when the intrinsic ventricular rate falls below a predetermined lower limit; pacemaker activity is suppressed when the intrinsic heart rate is faster (ventricular inhibited). The escape interval (the time between the last intrinsic beat and the paced beat) is equivalent to the rate at which the pacemaker is set to activate. Similar to atrial pacing, if the pacemaker is set at 60",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    the pacemaker will only pace the ventricle if the rate falls below 60",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    or there is a pause of one second (60",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    &divide; 60",
"    <span class=\"nowrap\">",
"     sec/min).",
"    </span>",
"    If the native rate is slow, there will be 100 percent ventricular pacing (",
"    <a class=\"graphic graphic_figure graphicRef78390 \" href=\"UTD.htm?18/41/19097\">",
"     figure 1",
"    </a>",
"    ). The electrocardiogram may have evidence of fusion or pseudofusion beats if the pacemaker rate and intrinsic heart rate are nearly identical, and the native and paced QRS complex occur simultaneously.",
"   </p>",
"   <p>",
"    Fusion beats show a QRS morphology that is a mixture of the native and paced QRS complex. Pseudofusion beats show a native QRS with a pacing spike just after the beginning of the QRS complex, giving the appearance of pacing, but since the pacing spike is after the ventricle has started to depolarize, the pacing stimulus is delivered during the refractory period and does not capture the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DUAL CHAMBER ATRIOVENTRICULAR SEQUENTIAL PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV sequential pacing appears on the electrocardiogram as pacemaker spikes before the P wave and QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef78036 \" href=\"UTD.htm?22/40/23176\">",
"     waveform 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .) If the native atrial rate is faster than the programmed lower rate of the pacemaker, there will be no pacing spike prior to the P wave, since the P wave originates from the sinus node (or another atrial location). Depending on device programming and atrioventricular conduction, there is either a paced or a native QRS. The paced QRS has a bizarre morphology resembling a left bundle branch block or a ventricular complex (",
"    <a class=\"graphic graphic_waveform graphicRef72105 \" href=\"UTD.htm?22/57/23447\">",
"     waveform 4",
"    </a>",
"    ). If there is a native QRS, the morphology is normal and narrow, but may be wide if there is an underlying bundle branch block.",
"   </p>",
"   <p>",
"    The morphology of the P wave depends upon the location of the lead within the right atrium; it may be upright, biphasic, or negative and the amplitude may be normal, increased, or diminutive. The PR interval is determined by the pacemaker and represents the delay between the atrial and ventricular stimuli; the pacemaker is essentially functioning as the AV node. The second or ventricular spike is followed by a QRS complex that is bizarre and usually has a left bundle branch block morphology since the ventricular lead is typically in the right ventricle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437718510\">",
"    <span class=\"h1\">",
"     BIVENTRICULAR PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard ventricular pacing is from the right ventricle. Hence, the QRS complex has a left bundle branch block morphology as the impulse originates from the right ventricle and is conducted to the left ventricle (a right to left direction). This produces a tall and broad R wave in leads I, V5, and V6 and a deep QS complex in lead V1.",
"   </p>",
"   <p>",
"    With biventricular pacing, also known as cardiac resynchronization therapy (CRT) there are pacing leads in the right atrium, right ventricle and the coronary sinus, which results in stimulation of the left ventricle (",
"    <a class=\"graphic graphic_waveform graphicRef64812 \" href=\"UTD.htm?25/15/25844\">",
"     waveform 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Implantation and other considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sometimes the coronary sinus lead is replaced by an epicardial or endocardial left ventricular lead. Ventricular pacing occurs from both the right ventricular and coronary",
"    <span class=\"nowrap\">",
"     sinus/left",
"    </span>",
"    ventricular leads. The timing between the leads can be changed so that one lead is paced prior to the other or they can be paced simultaneously. Depending on the timing of pacing between the two leads, the QRS axis and morphology may change significantly.",
"   </p>",
"   <p>",
"    Assuming left ventricular pacing occurs simultaneously or prior to right ventricular pacing, activation of the left ventricle precedes right ventricular activation. Therefore, the initial impulse direction is left to right. The most important electrocardiographic lead that demonstrates this impulse direction is lead I, which is a bipolar lead that looks at the impulse as it travels from the right to left. Initial activation of the left ventricle generates an impulse that is directed from left to right, producing a negative waveform (Q wave) in lead I. Therefore, with biventricular pacing lead, lead I will have an initial Q wave or a QS complex. In addition, leads V5-V6 also frequently demonstrate a QS complex. However, this is not definitive for biventricular pacing, as a left bundle branch block may be associated with a QS complex in these leads. Biventricular pacing will also produce a tall R wave in lead V1, as the impulses are directed toward this lead. However, this QRS complex morphology may be seen with a right ventricular pacing electrode located at the interventricular septum. Therefore, while a QS complex in leads V5-V6 and a tall R wave in lead V1 are strongly suggestive of a biventricular pacemaker, an initial Q wave or a QS complex in lead I is definitive for left or biventricular pacing. In addition, if there is a significant difference between right and left ventricular pacing stimuli, two ventricular pacing spikes may be seen, with the second one occurring after the start of the QRS . This may be confused with pacemaker malfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PACER MALFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacemakers may malfunction either by failure of capture or sensing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21737?source=see_link\">",
"     \"Pacing system malfunction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Loss of capture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacemaker malfunction with inconsistent capturing (atrium or ventricle) can be diagnosed from the electrocardiogram when there are pacemaker spikes that are not followed immediately by either a P wave or QRS complex (",
"    <a class=\"graphic graphic_figure graphicRef87026 \" href=\"UTD.htm?42/0/43017\">",
"     figure 2",
"    </a>",
"    ). Non-capture may be intermittent, so that only occasional non-captured pacemaker stimuli are seen, or persistent, where no native complexes follow pacing spikes. In the latter cases, if intrinsic cardiac activity is present, the pacemaker stimuli are dissociated from the native P waves or QRS complexes. There may be no underlying cardiac activity in severe cases of loss of capture and asystole is seen. Loss of capture may be due to lead dislodgement or malposition, inflammation or fibrosis at the",
"    <span class=\"nowrap\">",
"     lead/tissue",
"    </span>",
"    interface, low pacemaker output, lead failure, or battery depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Failure of sensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacemakers may have undersensing of native cardiac activity or oversensing of non-physiologic signal (",
"    <a class=\"graphic graphic_waveform graphicRef56417 \" href=\"UTD.htm?15/25/15768\">",
"     waveform 6",
"    </a>",
"    ). In undersensing, the pacemaker does not see the native electrical signal in the chamber of interest, and will deliver a pacing stimulus at the lower rate for the atrium or after the programmed atrioventricular delay in the ventricle. Therefore, there will be a pacing spike in the middle of or after the beginning of the native P wave or QRS, or have no relation to the underlying cardiac activity. Depending on the refractoriness of the tissue, this pacing spike may or may not capture. The interval between the native and paced complexes is variable. Note that when pacemakers are turned to asynchronous modes (eg, AOO, VOO, DOO), they are programmed not to sense intrinsic cardiac signal and will have the appearance of undersensing.",
"   </p>",
"   <p>",
"    It may seem that there is failure to sense a premature atrial or ventricular premature beat in some cases that are not actually representative of pacemaker malfunction. It may be dependent instead upon the timing of the premature beat, which may not be sensed by the pacemaker if the signal falls within a refractory period.",
"   </p>",
"   <p>",
"    Oversensing may occur when the device sees a signal that does not originate from within the chamber of interest. This may be from electromagnetic interference, such as from electrocautery or other electrical interference, diaphragmatic myopotentials, pectoral muscle myopotentials if in a unipolar mode, lead fracture, or far field signals from another cardiac chamber. In oversensing, the device inhibits pacing. Therefore, no pacing spikes are seen at the expected time on the ECG, and unless there is intrinsic cardiac activity, there will be asystole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90656611\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pacemaker leads may be placed in the right atrium, right ventricle, and coronary",
"      <span class=\"nowrap\">",
"       sinus/left",
"      </span>",
"      ventricle.",
"     </li>",
"     <li>",
"      If there is native cardiac activity faster than the programmed intervals, the P wave and QRS complex will resemble normal patterns. If there is slow cardiac activity, the ECG shows a pacing spike followed by a P wave or QRS complex. The morphology of a paced P wave may resemble or look different than the native P wave. The morphology of a paced QRS has a LBBB configuration and is usually negative in the inferior leads.",
"     </li>",
"     <li>",
"      The QRS complex with biventricular pacing will vary depending on right ventricular and left ventricular timing, but often has a tall R wave in V1 and an initial Q wave or QS complex in lead I.",
"     </li>",
"     <li>",
"      Loss of pacemaker capture is defined by a pacing spike with no P wave or QRS complex, when the myocardium is physiologically capable of being depolarized.",
"     </li>",
"     <li>",
"      Undersensing occurs when the pacemaker does not see native cardiac activity and paces inappropriately in the middle of or after a P wave or QRS complex, or has no relationship to the native cardiac signal.",
"     </li>",
"     <li>",
"      Oversensing occurs when the pacemaker sees non-physiology activity and inhibits pacing. No pacing spikes are seen at the expected times.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90656317\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2122 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_996=[""].join("\n");
var outline_f0_62_996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H90656611\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90656333\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ATRIAL PACING ONLY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VENTRICULAR PACING ONLY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DUAL CHAMBER ATRIOVENTRICULAR SEQUENTIAL PACING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H437718510\">",
"      BIVENTRICULAR PACING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PACER MALFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Loss of capture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Failure of sensing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90656611\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90656317\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2122|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/41/19097\" title=\"figure 1\">",
"      Ventricular pacing with 100 percent capture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/0/43017\" title=\"figure 2\">",
"      Pacemaker failure to capture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2122|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?34/31/35318\" title=\"waveform 1\">",
"      Atrial pacemaker tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?13/8/13447\" title=\"waveform 2\">",
"      Ventricular demand pacemaker tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?22/40/23176\" title=\"waveform 3\">",
"      AV sequential pacing tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?22/57/23447\" title=\"waveform 4\">",
"      Atrial sensing pacer tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?25/15/25844\" title=\"waveform 5\">",
"      Biventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?15/25/15768\" title=\"waveform 6\">",
"      Pacer nonsensing tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21737?source=related_link\">",
"      Pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_62_997="Dexamethasone (ophthalmic): Drug information";
var content_f0_62_997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexamethasone (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17172?source=see_link\">",
"    see \"Dexamethasone (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/51/5941?source=see_link\">",
"    see \"Dexamethasone (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8015642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxidex&reg;;",
"     </li>",
"     <li>",
"      Ozurdex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8015643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diodex&reg;;",
"     </li>",
"     <li>",
"      Maxidex&reg;;",
"     </li>",
"     <li>",
"      Ozurdex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8016748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-inflammatory Agent, Ophthalmic;",
"     </li>",
"     <li>",
"      Corticosteroid, Ophthalmic;",
"     </li>",
"     <li>",
"      Corticosteroid, Otic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8015738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anti-inflammatory:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Solution: Instill 1-2 drops into conjunctival sac every hour during the day and every other hour during the night; gradually reduce dose to 1 drop every 4 hours, then to 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suspension: Instill 1-2 drops into conjunctival sac up to 4-6 times/day; may use hourly in severe disease; taper prior to discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Solution: Initial: Instill 3-4 drops into the aural canal 2-3 times a day; reduce dose gradually once a favorable response is obtained. Alternately, may pack the aural canal with a gauze wick saturated with the solution; remove from the ear after 12-24 hours. Repeat as necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Macular edema (following BRVO or CRVO):",
"     </b>",
"     Ocular implant (Ozurdex&reg;): Intravitreal injection: 0.7 mg implant injected in affected eye",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Noninfective uveitis:",
"     </b>",
"     Ocular implant (Ozurdex&reg;): Intravitreal injection: 0.7 mg implant injected in affected eye",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8015739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Solution/suspension: Use cautiously in the elderly in the smallest possible dose.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15827037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15827038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8016302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, intravitreal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ozurdex&reg;: 0.7 mg (1s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as phosphate [drops]: 0.1% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxidex&reg;: 0.1% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8015645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Ophthalmic solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8016290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic solution, suspension: Remove soft contact lenses prior to using solutions containing benzalkonium chloride. Do not touch tip of container to eye. Shake suspension well prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ophthalmic solution may also be administered otically. Prior to use, clean the aural canal thoroughly and sponge dry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic implant (intravitreal injection): Ozurdex&reg;: Administer under controlled aseptic conditions (eg, sterile gloves, sterile drape, sterile eyelid speculum). Adequate anesthesia and a broad-spectrum bactericidal agent should be administered prior to injection. In the sterile field, open foil pouch, remove applicator, and pull the safety tab straight off of the applicator (do not twist or flex the tab). If administration is required in the second eye, a new applicator should be used and the sterile field, syringe, gloves, drapes, and eyelid speculum should be changed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8083884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of steroid-responsive inflammatory conditions such as allergic conjunctivitis, iritis, or cyclitis; symptomatic treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The ophthalmic solution is also indicated for otic use to treat steroid-responsive inflammatory conditions of the external auditory meatus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic intravitreal implant (Ozurdex&reg;): Treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO); treatment of noninfective uveitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8015641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexamethasone may be confused with desoximetasone, dextroamphetamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Maxidex&reg; may be confused with Maxzide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10118945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Intravitreal implant (Ozurdex&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Ocular: Intraocular pressure increased (25%), conjunctival hemorrhage (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Pain (8%), conjunctival hyperemia (7%), cataract (5%; incidence increases in patients requiring a second injection), hypertension (5%), vitreous detachment (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Corneal edema, device dislocation, endophthalmitis, hypotony, implant misplacement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Ophthalmic solution/suspension:",
"     </b>",
"     Frequency not defined: Ocular: Burning, cataract formation, filtering blebs, glaucoma (with optic nerve damage), perforation of globe, secondary ocular infections, stinging, visual acuity defects, visual field defects",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8015654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexamethasone or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension/solution: Viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis, vaccinia, varicella); mycobacterial or fungal infection of the eye; the solution should also not be used for otic indications if perforation of a drum membrane is present",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravitreal implant: Advanced glaucoma; active or suspected ocular or periocular infections; anterior chamber intraocular lens (ACIOL) and aphakic eyes with rupture of posterior lens capsule",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8083886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use may increase the hazard of secondary ocular infections. May mask infection or enhance existing infection. The possibility of persistent corneal fungal infection should be considered after prolonged use. Corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Avoid prolonged use, which may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Monitor intraocular pressure if topical ophthalmic products are used for 10 days or longer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular disease: Perforations may occur in diseases which cause thinning of the cornea or sclera.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Ophthalmic solution and suspension contain benzalkonium chloride which may be absorbed by contact lenses; contact lens should not be worn during treatment of ophthalmic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Intravitreal implant: Endophthalmitis, ocular inflammation, intraocular pressure elevations and retinal detachments may occur with intravitreal injection. Intraocular pressure elevations peak ~8 weeks following injection; prolonged monitoring of intraocular pressure may be required. A risk of implant migration into the anterior chamber may be present if the posterior capsule of the lens is absent or torn. Temporary blurring may occur following intravitreal injections; patients should not drive until this resolves.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8015662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8083888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9890216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies following use of ophthalmic dexamethasone.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9890217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9890218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although it is not known if detectable concentrations are found in breast milk following application of ophthalmic dexamethasone, the manufacturer recommends caution be used if administered to a nursing woman.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8016304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Implant",
"     </b>",
"     (Ozurdex Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.7 mg (1): $1554.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dexamethasone Sodium Phosphate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (5 mL): $21.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Maxidex Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (5 mL): $68.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8016292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic solution/suspension: Intraocular pressure (with use &gt;10 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic implant (intravitreal injection): Following injection, monitor for increased intraocular pressure and endophthalmitis; check for perfusion of optic nerve head immediately after injection, tonometry within 30 minutes, biomicroscopy between 2-7 days after injection.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betam-Ophtal (ID);",
"     </li>",
"     <li>",
"      Decadron (CO, EC);",
"     </li>",
"     <li>",
"      Dexa-Sine (BE);",
"     </li>",
"     <li>",
"      Dexa-Sine SE (NO);",
"     </li>",
"     <li>",
"      Dexafree (CH, FR, PL, PT);",
"     </li>",
"     <li>",
"      Dexagel (TH);",
"     </li>",
"     <li>",
"      Dian Shu (CL);",
"     </li>",
"     <li>",
"      Isopto-Dex (DE);",
"     </li>",
"     <li>",
"      Isopto-Maxidex (AR, CO, NO, PY);",
"     </li>",
"     <li>",
"      Maradex (VE);",
"     </li>",
"     <li>",
"      Maxidex (AE, AU, BE, BF, BH, BJ, BR, CH, CI, CN, CY, CZ, DK, EE, EG, ET, FR, GB, GH, GM, GN, GR, HN, IE, IL, IQ, IR, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NZ, OM, PE, PH, PK, QA, RU, SA, SC, SD, SE, SG, SL, SN, SY, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nexadron Oftal (AR);",
"     </li>",
"     <li>",
"      Oftan Dexa (EE, FI);",
"     </li>",
"     <li>",
"      Opnol (SE);",
"     </li>",
"     <li>",
"      Ozurdex (CH, CO, CZ, DE, DK, EE, FR, GB, HK, NO, PL, PT, SE, SG);",
"     </li>",
"     <li>",
"      Santeson (PH);",
"     </li>",
"     <li>",
"      Spersadex (CH, DE, HK, NO, ZA);",
"     </li>",
"     <li>",
"      Sterodex (IL);",
"     </li>",
"     <li>",
"      Thilodexine (GR);",
"     </li>",
"     <li>",
"      Visumetazone (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10893630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of neutrophil migration, decreased production of inflammatory mediators, and reversal of increased capillary permeability; suppresses normal immune response.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10118950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Ocular implant: BRVO/CRVO: Improvement observed in 20% to 30% of patients within first 2 months following intravitreal injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of effect: Ocular implant: BRVO/CRVO: 1-3 months (following onset of improvement)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Ocular implant: Systemic levels negligible in majority of patients (&le;50 pg/mL) &le;90 days following implant, highest systemic concentration observed: 94 pg/mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lowder C, Belfort R Jr, Lightman S, et al, \"Ozurdex HURON Study Group. Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis,\"",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2011, 129(5):545-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/997/abstract-text/21220619/pubmed\" id=\"21220619\" target=\"_blank\">",
"        21220619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9099 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_997=[""].join("\n");
var outline_f0_62_997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015642\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015643\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016748\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015738\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015739\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827037\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827038\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016302\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015645\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016290\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083884\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015641\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10118945\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015654\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083886\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299141\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015662\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083888\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9890216\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9890217\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9890218\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016304\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016292\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961969\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10893630\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10118950\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9099\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9099|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17172?source=related_link\">",
"      Dexamethasone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/51/5941?source=related_link\">",
"      Dexamethasone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14042?source=related_link\">",
"      Dexamethasone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41686?source=related_link\">",
"      Dexamethasone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/18/6442?source=related_link\">",
"      Dexamethasone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_62_998="Second degree atrioventricular block: Mobitz type II";
var content_f0_62_998=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second degree atrioventricular block: Mobitz type II",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/998/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/998/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/998/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/998/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/62/998/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/62/998/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/62/998/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse, either transient or permanent, from the atria to the ventricles due to an anatomic or functional impairment in the conduction system. The conduction can be delayed, intermittent, or absent. The commonly used terminology includes first degree AV block (slowed conduction without missed beats), second degree AV block (missed beats, often in a regular pattern, eg, 2:1, 3:2, or higher degrees of block), and third degree or complete AV block.",
"   </p>",
"   <p>",
"    In second degree AV block, some atrial impulses fail to reach the ventricles. Wenckebach described progressive delay between atrial and ventricular contraction and the eventual failure of an atrial beat to reach the ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/1\">",
"     1",
"    </a>",
"    ]. Mobitz subsequently divided second degree AV block into two subtypes, as determined by the findings on the electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mobitz type I AV block, in which progressive PR interval prolongation precedes a nonconducted P wave.",
"     </li>",
"     <li>",
"      Mobitz type II AV block, in which the PR interval remains unchanged prior to a P wave that suddenly fails to conduct to the ventricles.",
"     </li>",
"     <li>",
"      Advanced second degree AV block, in which two or more consecutive P waves are nonconducted. In contrast to third degree or complete heart block, however, some P waves continue to be conducted to the ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mobitz type II AV block will be reviewed here. Mobitz type I (Wenckebach) AV block and the etiology of AV block are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2169051\">",
"    <span class=\"h1\">",
"     SECOND DEGREE AV BLOCK: TYPE I VERSUS TYPE II",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with second degree AV block with a ratio of atrial to ventricular conduction that is not 2:1, the PR interval on the standard ECG can be used to distinguish Mobitz type I AV block and Mobitz type II AV block:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In Mobitz type I AV block, there is progressive PR interval prolongation for several beats preceding the nonconducted P wave (",
"      <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"UTD.htm?42/35/43573\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In Mobitz type II AV block, the PR interval remains unchanged prior to a P wave that suddenly fails to conduct to the ventricles (",
"      <a class=\"graphic graphic_waveform graphicRef58649 \" href=\"UTD.htm?33/33/34328\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distinction between Mobitz type I AV block and Mobitz type II AV block cannot be made from the ECG when 2:1 block is present. In this situation, every other beat is nonconducted and there is no opportunity to observe for possible PR prolongation that is characteristic of Mobitz type I AV block. To aid in the diagnosis, a long rhythm strip should be obtained or a previous ECG examined to try to find evidence of PR prolongation with nonconducted beats in a pattern other than 2:1 (eg, 3:2, 4:3, etc).",
"   </p>",
"   <p>",
"    Certain ECG features may add in differentiating Mobitz type I AV block from Mobitz type II AV block if a 2:1 block is present. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the PR interval of a conducted beat is very long (&gt;300 msec) or the QRS complex is narrow, the level of block is more likely to be in the AV node (type I).",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      is administered and there is enhanced AV nodal conduction resulting in less frequent nonconducted beats (ie, a 3:2 cycle), this confirms Mobitz type I AV block.",
"     </li>",
"     <li>",
"      Carotid sinus massage would be expected to worsen Mobitz type I AV block by slowing AV nodal conduction. In Mobitz type II AV block, however, carotid sinus massage could paradoxically result in the elimination of infranodal block by slowing the sinus rate to allow for a longer time for infranodal repolarization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobitz type II AV block almost always results from conduction system disease below the level of the AV node, occurring in the bundle of His in about 20 percent of cases and in the bundle branches in the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with bundle branch involvement also have axis shifts and QRS widening depending upon the location of the block. In addition, at least two-thirds of patients with this disorder also have bifascicular or even trifascicular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18308?source=see_link&amp;anchor=H7#H7\">",
"     \"Basic approach to delayed intraventricular conduction\", section on 'Bifascicular and trifascicular block'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12261?source=see_link\">",
"     \"Course and treatment of chronic bifascicular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    His bundle electrocardiography, performed as part of an invasive electrophysiologic (EP) study, shows that the nonconducted A wave (P wave on surface ECG) is followed by a His deflection, and not infrequently, a split His potential due to slowed intra-Hisian conduction of the conducted beat (",
"    <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"UTD.htm?28/37/29270\">",
"     waveform 3",
"    </a>",
"    ). Rarely, proximal His block does not demonstrate a His potential with the nonconducted beat, falsely suggesting that the block is in the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PR interval may be normal or slightly prolonged in Mobitz type II AV block, as compared to the increasing prolongation in PR interval in Mobitz type I AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobitz type II AV block can occur in older adults with age-related fibrous degeneration of the conduction system, in patients with certain heart diseases (eg, myocardial infarction with ischemia of the AV node), or in patients who are taking drugs that block the AV node (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , beta blockers, calcium channel blockers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mobitz type II AV block with only infrequent dropped beats in a patient with a normal sinus heart rate (ie, 60 to 100 beats per minute) may produce few or no symptoms. However, if the sinus rate is slow, or there are fewer conducted beats, there may be a significant reduction in cardiac output resulting in symptoms of hypoperfusion or heart failure.",
"   </p>",
"   <p>",
"    The failure of one or more P waves to conduct to the ventricles can lead to fatigue, lightheadedness, presyncope, or syncope (called Stokes-Adams attacks), since the lower intrinsic cardiac pacemakers are slower than junctional pacemakers (",
"    <a class=\"graphic graphic_waveform graphicRef64261 \" href=\"UTD.htm?6/55/7029\">",
"     waveform 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. An increase in heart rate due to exercise,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , or atrial pacing can worsen Mobitz type II AV block. Conversely, vagal maneuvers may slow the sinus rate, allow more time for excitability to recover in or below the bundle of His, thereby facilitating conduction across the AV node and improving Mobitz type II AV block.",
"   </p>",
"   <p>",
"    Unlike Mobitz type I AV block, which may be transient or temporary, Mobitz type II AV block is almost always permanent and",
"    <strong>",
"     frequently progresses",
"    </strong>",
"    to complete heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. The incidence of requiring insertion of a pacemaker is uncertain, varying in part on the presence or absence of other conduction disturbances, but also because no randomized trials of pacemakers versus medical treatment have been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2169405\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGY STUDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force published recommendations for the use of electrophysiologic testing in patients with AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/19\">",
"     19",
"    </a>",
"    ]. The two class I indications were symptomatic patients in whom His-Purkinje block is suspected but not proven to be the cause of symptoms, and patients with second or third degree AV block who remain symptomatic after pacemaker implantation in whom another arrhythmia is thought to be responsible for the symptoms.",
"   </p>",
"   <p>",
"    Electrophysiology studies may identify patients with Mobitz type II AV block who are at increased risk. However, since almost all such patients with irreversible disease are candidates for a permanent pacemaker, EP study is of limited value and not usually performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H14#H14\">",
"     \"Indications for permanent cardiac pacing\", section on 'Role of EP study'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of Mobitz type II AV block begins by looking for and correcting reversible causes of slowed conduction such as myocardial ischemia, increased vagal tone, and drugs that depress conduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no reversible causes are present, treatment of Mobitz type II AV block should include the avoidance of medications that impair AV conduction (when possible), and permanent pacemaker placement in nearly all patients. Unlike asymptomatic patients with Mobitz type I AV block who do not require any specific therapy, patients with Mobitz type II AV block have a high likelihood of progressing to symptomatic Mobitz type II AV block or complete heart block and should be considered candidates for pacemaker insertion on initial presentation. Detailed reviews of the indications for permanent pacemaker placement and of the modes of cardiac pacing are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H10#H10\">",
"     \"Indications for permanent cardiac pacing\", section on 'Acquired AV block'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pacemaker indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with Mobitz type II AV block, we proceed with implantation of a permanent pacemaker. This approach is in agreement with the recommendations the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    device guidelines recommendations. We agree with the guidelines for implantation of cardiac pacemakers in patients with AV block that have been established by a task force formed jointly by the American College of Cardiology, the American Heart Association, and the Heart Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines and recommendations for implantation of cardiac devices (",
"    <a class=\"graphic graphic_table graphicRef81080 \" href=\"UTD.htm?23/23/23933\">",
"     table 1",
"    </a>",
"    ) and (",
"    <a class=\"graphic graphic_figure graphicRef71370 \" href=\"UTD.htm?28/21/29023\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/62/998/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neuromuscular diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of neuromuscular diseases are associated with AV block. These include myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb's dystrophy (limb-girdle), and peroneal muscular atrophy. These patients represent a special class and are treated more aggressively with pacemakers due to the potential for unpredictably rapid progression of conduction disease (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link\">",
"     \"Inherited syndromes associated with cardiac disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H23#H23\">",
"     \"Indications for permanent cardiac pacing\", section on 'Neuromuscular diseases'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pacing mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with Mobitz type II AV block undergoing pacemaker insertion, we implant a dual chamber DDD pacemaker whenever possible in an effort to maintain physiologic AV synchrony (",
"    <a class=\"graphic graphic_figure graphicRef71370 \" href=\"UTD.htm?28/21/29023\">",
"     figure 1",
"    </a>",
"    ). Single chamber VVI pacemakers were most commonly used in the past, and are still used in the emergent setting for temporary pacing or in patients with atrial tachyarrhythmias. However, single chamber VVI pacemakers do not allow for normal AV synchrony, the loss of which is hemodynamically unfavorable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link&amp;anchor=H25#H25\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Physiologic pacing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=see_link\">",
"       \"Patient information: Heart block in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2169553\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse from the atria to the ventricles due to an anatomic or functional impairment in the conduction system. In Mobitz type II AV block, the PR interval remains unchanged prior to a P wave that suddenly fails to conduct to the ventricles, whereas in Mobitz type I AV block, there is progressive PR interval prolongation for several beats preceding the nonconducted P wave. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mobitz type II AV block with only infrequent dropped beats in a patient with a normal sinus heart rate (ie, 60 to 100 beats per minute) may produce few or no symptoms. However, if the sinus rate is slow, or there are fewer conducted beats, there may be a significant reduction in cardiac output and symptoms of hypoperfusion or heart failure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology and clinical implications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiating treatment for Mobitz type II AV block, reversible causes of slowed conduction such as myocardial ischemia and medications should be excluded. If no reversible causes are present, treatment of Mobitz type II AV block should involve permanent pacemaker placement in nearly all patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with Mobitz type II AV block undergoing pacemaker insertion, we implant a dual chamber DDD pacemaker whenever possible in an effort to maintain physiologic AV synchrony. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pacing mode'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/1\">",
"      Wenckebach KF. Zur Analyse der unregelm&auml;ssigen Pulses. Ztschr klin Med 1899; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/2\">",
"      Mobitz W. &Uuml;ber die unvollst&auml;ndige St&ouml;rung der Erregungs&uuml;berleitung zwischen Vorhof und Kammer des menschlichen Herzens. Z Gesamte Exp Med 1924; 41:180.",
"     </a>",
"    </li>",
"    <li>",
"     Narula OS. Conduction disorders in the AV transmission system. In: Cardiac Arrhythmias, Dreifus L, Likoff W (Eds), Grune and Stratton, New York 1973. p.259.",
"    </li>",
"    <li>",
"     Peuch P. The value in intracardiac recordings. In: Cardiac Arrhythmias, Krikler D, Gododwin JF (Eds), Saunders, Philadelphia 1975. p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/5\">",
"      Puech P, Wainwright RJ. Clinical electrophysiology of atrioventricular block. Cardiol Clin 1983; 1:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/6\">",
"      Langendorf R, Cohen H, Gozo EG Jr. Observations on second degree atrioventricular block, including new criteria for the differential diagnosis between type I and type II block. Am J Cardiol 1972; 29:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/7\">",
"      Goodfriend MA, Barold SS. Tachycardia-dependent and bradycardia-dependent Mobitz type II atrioventricular block within the bundle of His. Am J Cardiol 1974; 33:908.",
"     </a>",
"    </li>",
"    <li>",
"     Narula OS. Atrioventricular block. In: Cardiac Arrhythmias: Electrophysiology, Diagnosis and Management, Williams &amp; Wilkins, Baltimore 1979. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/9\">",
"      PACKARD JM, GRAETTINGER JS, GRAYBIEL A. Analysis of the electrocardiograms obtained from 1000 young healthy aviators; ten year follow-up. Circulation 1954; 10:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/10\">",
"      Rosen KM, Dhingra RC, Loeb HS, Rahimtoola SH. Chronic heart block in adults. Clinical and electrophysiological observations. Arch Intern Med 1973; 131:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/11\">",
"      Gupta PK, Lichstein E, Chadda KD. Chronic His bundle block. Clinical, electrocardiographic, electrophysiological, and follow-up studies on 16 patients. Br Heart J 1976; 38:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/12\">",
"      Narula OS, Narula JT. Junctional pacemakers in man. Response to overdrive suppression with and without parasympathetic blockade. Circulation 1978; 57:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/13\">",
"      Amat-y-Leon F, Dhingra R, Denes P, et al. The clinical spectrum of chronic His bundle block. Chest 1976; 70:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/14\">",
"      DONOSO E, ADLER LN, FRIEDBERG CK. UNUSUAL FORMS OF SECOND-DEGREE ATRIOVENTRICULAR BLOCK, INCLUDING MOBITZ TYPE-II BLOCK, ASSOCIATED WITH THE MORGAGNI-ADAMS-STOKES SYNDROME. Am Heart J 1964; 67:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/15\">",
"      Dhingra RC, Denes P, Wu D, et al. The significance of second degree atrioventricular block and bundle branch block. Observations regarding site and type of block. Circulation 1974; 49:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/16\">",
"      Dhingra RC, Palileo E, Strasberg B, et al. Significance of the HV interval in 517 patients with chronic bifascicular block. Circulation 1981; 64:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/17\">",
"      Strasberg B, Amat-Y-Leon F, Dhingra RC, et al. Natural history of chronic second-degree atrioventricular nodal block. Circulation 1981; 63:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/18\">",
"      Recommendations for pacemaker prescription for symptomatic bradycardia. Report of a working party of the British Pacing and Electrophysiology Group. Br Heart J 1991; 66:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/19\">",
"      Zipes DP, DiMarco JP, Gillette PC, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 1995; 26:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/62/998/abstract/20\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 910 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_998=[""].join("\n");
var outline_f0_62_998=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2169553\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2169051\">",
"      SECOND DEGREE AV BLOCK: TYPE I VERSUS TYPE II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY AND CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2169405\">",
"      ELECTROPHYSIOLOGY STUDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pacemaker indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pacing mode",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2169553\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/910\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/910|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/21/29023\" title=\"figure 1\">",
"      Pacemaker algorithm AV block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/910|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/23/23933\" title=\"table 1\">",
"      ACC AHA HRS AV block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/910|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43573\" title=\"waveform 1\">",
"      ECG Mobitz type I AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?33/33/34328\" title=\"waveform 2\">",
"      Mobitz type II second degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/37/29270\" title=\"waveform 3\">",
"      ECG Mobitz type II AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/55/7029\" title=\"waveform 4\">",
"      ECG complete HB with Mobitz type II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18308?source=related_link\">",
"      Basic approach to delayed intraventricular conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12261?source=related_link\">",
"      Course and treatment of chronic bifascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=related_link\">",
"      Patient information: Heart block in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_62_999="Atomoxetine: Drug information";
var content_f0_62_999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atomoxetine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/2/6182?source=see_link\">",
"    see \"Atomoxetine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"    see \"Atomoxetine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Strattera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atomoxetine&reg;;",
"     </li>",
"     <li>",
"      Mylan-Atomoxetine;",
"     </li>",
"     <li>",
"      PMS-Atomoxetine;",
"     </li>",
"     <li>",
"      Sandoz-Atomoxetine;",
"     </li>",
"     <li>",
"      Strattera&reg;;",
"     </li>",
"     <li>",
"      Teva-Atomoxetine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Norepinephrine Reuptake Inhibitor, Selective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Treatment of ADHD:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Atomoxetine may be discontinued without the need for tapering dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 40 mg/day, increased after minimum of 3 days to ~80 mg/day; may administer as either a single daily dose or 2 evenly divided doses in morning and late afternoon/early evening. May increase to 100 mg/day in 2-4 additional weeks to achieve optimal response. Maximum daily dose: 100 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dosage adjustment in patients receiving strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) or patients known to be CYP2D6 poor metabolizers: Initial: 40 mg/day; if tolerating therapy but inadequate response, may increase after minimum of 4 weeks to 80 mg/day. Maximum daily dose: 80 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 40 mg/day for 7-14 days (Step 1); if tolerated, may increase dose at 7-14 day intervals to 60 mg/day (Step 2) then to 80 mg/day (Step 3). If optimal response is not obtained after 2-4 additional weeks, may increase to a maximum dose of 100 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dosage adjustment in patients receiving strong CYP2D6 inhibitors: Initial: 40 mg/day; may increase to next dosage level after 14 days if previous dose is well tolerated but response is inadequate.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling does not include specific dosing recommendations in regards to patients who are poor CYP2D6 metabolizers although similar dose reductions would appear necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F137809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"      see \"Atomoxetine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of ADHD:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Atomoxetine may be discontinued without the need for tapering dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &ge;6 years and &le;70 kg:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 0.5 mg/kg/day, increase after minimum of 3 days to ~1.2 mg/kg/day; may administer as either a single daily dose or 2 evenly divided doses in morning and late afternoon/early evening. Maximum daily dose: 1.4 mg/kg or 100 mg, whichever is less.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dosage adjustment in patients receiving strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) or patients known to be CYP2D6 poor metabolizers: Initial: 0.5 mg/kg/day; if tolerating therapy but inadequate response, may increase after minimum of 4 weeks to 1.2 mg/kg/day. Maximum daily dose: 1.2 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: ~0.5 mg/kg/day for 7-14 days (Step 1); if tolerated, may increase to ~0.8 mg/kg/day for 7-14 days (Step 2), then to ~1.2 mg/kg/day (Step 3); re-evaluate after &ge;30 days and adjust for response if necessary. Maximum daily dose: 1.4 mg/kg or 100 mg, whichever is less.",
"     <b>",
"      Note:",
"     </b>",
"     Children should weigh at least 20 kg at the time of initiation as 10 mg is the lowest available capsule strength and capsules are to be swallowed whole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dosing recommendations according to weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial (Step 1):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     20-29 kg: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     30-44 kg: 18 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     45-64 kg: 25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     65-70 kg: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First titration (Step 2):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     20-29 kg: 18 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     30-44 kg: 25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     45-64 kg: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     65-70 kg: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second titration (Step 3):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     20-29 kg: 25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     30-44 kg: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     45-64 kg: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     65-70 kg: 80 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dosage adjustment in patients receiving strong CYP2D6 inhibitors: Initial: 0.5 mg/kg/day; may increase to next dosage level after 14 days if previous dose is well tolerated but response is inadequate.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling does not include specific dosing recommendations in regards to patients who are poor CYP2D6 metabolizers although similar dose reductions would appear necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Children &ge;6 years and &gt;70 kg:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F137802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use has not been evaluated in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F137803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F137804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate impairment (Child-Pugh class B): All doses should be reduced to 50% of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): All doses should be reduced to 25% of normal.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Strattera&reg;: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089138.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089138.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F137781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food as a single daily dose in the morning or as two evenly divided doses in morning and late afternoon/early evening. Swallow capsules whole; do not open capsules. If opened accidentally, do not touch eyes; wash hands immediately (product is an ocular irritant).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F137780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention deficit/hyperactivity disorder (ADHD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8002173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       AtoMOXetine may be confused with atorvaSTATin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported in children and adults; some adverse reactions may be increased in &ldquo;poor metabolizers&rdquo; (CYP2D6).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 19%), insomnia (2% to 15%), somnolence (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (21%), nausea (7% to 21%), abdominal pain (7% to 18%), appetite decreased (11% to 16%), vomiting (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Systolic blood pressure increased (4% to 5%), diastolic pressure increased (&le;4%), palpitation (3%), flushing (&ge;2%), tachycardia (&le;2%), orthostatic hypotension (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue/lethargy (6% to 9%), dizziness (5% to 6%), irritability (&le;6%), chills (3%), sleep disturbance (3%), mood swings (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis (4%), rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (8%), dysmenorrhea (6%), libido decreased (4%), menstruation disturbance (2%), orgasm abnormal (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (1% to 9%), dyspepsia (4%), anorexia (&lt;3%), weight loss (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Erectile disturbance (9%), urinary hesitation/retention (7%), dysuria (3%), ejaculatory disturbance (3%), prostatitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (3% adults; postmarketing observation in children), tremor (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Mydriasis (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinus headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Jittery feeling (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Aggressiveness, agitation, akathisia, allergic reactions, allergy, anaphylaxis, angioedema, anxiety, delusional thinking, depression, flatulence, growth suppression (children), hallucinations, hepatotoxicity, hostility, hyperhidrosis, hypoesthesia, hypomania, impulsiveness, jaundice, mania, MI, panic attacks, paresthesia, pelvic pain, peripheral vascular instability, priapism, pruritus, QT prolongation, Raynaud&rsquo;s phenomenon, seizure (including patients with no prior history or known risk factors for seizure), stroke, suicidal ideation, syncope, tics, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F137784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atomoxetine or any component of the formulation; use with or within 14 days of MAO inhibitors; narrow-angle glaucoma; current or past history of pheochromocytoma; severe cardiovascular disorders in which the condition would be expected to deteriorate with clinically relevant blood pressure or heart rate increases",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Symptomatic cardiovascular diseases, moderate-to-severe hypertension; advanced arteriosclerosis; uncontrolled hyperthyroidism",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F137769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aggressive behavior: New or worsening symptoms of hostility or aggressive behaviors have been associated with atomoxetine, particularly with the initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Angioneurotic edema, urticaria, and rash may occur (rare).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: CNS stimulant use has been associated with serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke, and MI in adults). These products should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Use may be associated with rare but severe hepatotoxicity, including hepatic failure; discontinue and do not restart if signs or symptoms of hepatotoxic reaction (eg, jaundice, pruritus, flu-like symptoms) or laboratory evidence of liver injury are noted. The majority of reported cases occurred within 120 days of initiation of therapy. Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Use with caution in patients who are poor metabolizers of CYP2D6 metabolized drugs (\"poor metabolizers\"); bioavailability increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostasis: Orthostasis and subsequent syncope may occur. Avoid use in patients predisposed to hypotension, or with conditions associated with abrupt heart rate or blood pressure changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Priapism has been associated with use (rarely).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ADHD and comorbidities: Randomized, controlled trials have demonstrated that atomoxetine does not worsen anxiety in patients with existing anxiety disorders or tics related to Tourette&rsquo;s disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular or cerebrovascular conditions that might be exacerbated by increases in blood pressure or heart rate.  CYP2D6 poor metabolizers may experience greater increases in blood pressure and heart rate effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use caution in patients with a history of psychotic illness or bipolar disorder; therapy may induce mixed/manic disorder or psychotic symptoms. Atomoxetine is not approved for major depressive disorder; patients presenting with depressive symptoms should be screened for bipolar disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary retention: Use with caution in patients with a history of urinary retention or bladder outlet obstruction; may cause urinary retention/hesitancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 poor metabolizers: Dosage adjustments are recommended in patients known to be CYP2D6 poor metabolizers; these patients have increased exposure to atomoxetine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Use with caution in pediatric patients; may be an increased risk of suicidal ideation.",
"     </b>",
"     Closely monitor for clinical worsening, suicidality, or unusual changes in behavior; especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. Growth should be monitored during treatment. Height and weight gain may be reduced during the first 9-12 months of treatment, but should recover by 3 years of therapy. Safety and efficacy have not been evaluated in pediatric patients &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: AtoMOXetine may enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May increase the serum concentration of AtoMOXetine. Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Antidepressants (Selective Norepinephrine Reuptake Inhibitor) may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3089304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased pup weight and survival were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit to the mother outweighs possible risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F137787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F137785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Strattera Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $224.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18 mg (30): $224.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $224.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $243.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (30): $243.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $263.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $263.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F137777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient growth (weight/height gain in children); attention, hyperactivity, anxiety, worsening of aggressive behavior or hostility; blood pressure and pulse (baseline and following dose increases and periodically during treatment)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Family members and caregivers need to monitor patient daily for emergence of irritability, agitation, unusual changes in behavior, and suicide ideation. Pediatric patients should be monitored closely for suicidality, clinical worsening, or unusual changes in behavior, especially during the initial for months of therapy or at times of dose changes. Appearance of symptoms needs to be immediately reported to healthcare provider.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk.  Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F855137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abretia (PE);",
"     </li>",
"     <li>",
"      Attentrol (IN);",
"     </li>",
"     <li>",
"      Passiva (PE);",
"     </li>",
"     <li>",
"      Recit (AR);",
"     </li>",
"     <li>",
"      Strattera (AR, AT, AU, BE, BG, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, FI, FR, GB, GR, GT, HK, HN, IE, IT, KP, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, SE, SG, SV, TH, TW);",
"     </li>",
"     <li>",
"      Xenocy (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively inhibits the reuptake of norepinephrine (Ki 4.5nM) with little to no activity at the other neuronal reuptake pumps or receptor sites.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F137783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.: 0.85 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%, primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP2D6 and CYP2C19; forms metabolites (4-hydroxyatomoxetine, active, equipotent to atomoxetine; N-desmethylatomoxetine in poor metabolizers, limited activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 63% in extensive metabolizers; 94% in poor metabolizers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Atomoxetine: 5 hours (up to 24 hours in poor metabolizers); Active metabolites: 4-hydroxyatomoxetine: 6-8 hours; N-desmethylatomoxetine: 6-8 hours (34-40 hours in poor metabolizers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80%, as conjugated 4-hydroxy metabolite); feces (17%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/999/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Habel LA, Cooper WO, Sox CM, et al, &ldquo;ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,&rdquo; 2011,",
"      <i>",
"       JAMA",
"      </i>",
"      , 306(24):2673-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/999/abstract-text/22161946/pubmed\" id=\"22161946\" target=\"_blank\">",
"        22161946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at  www.nice.org.uk/cg072",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/62/999/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8787 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_62_999=[""].join("\n");
var outline_f0_62_999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708625\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137799\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855136\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137817\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137801\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137809\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137802\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137803\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137804\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137779\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137765\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874384\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137781\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137780\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002173\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137815\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137784\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137769\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137810\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137773\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3089304\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137775\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137786\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137807\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137787\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137785\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137777\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855137\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137768\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137783\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8787|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/2/6182?source=related_link\">",
"      Atomoxetine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=related_link\">",
"      Atomoxetine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
